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ABSTRACT
UTILIZATION OF PLACEBO RESPONSE IN DOUBLE-BLIND
PSYCHOPHARMACOLOGICAL STUDIES, CONTEXTUAL PERSPECTIVE
MARGARITA O. ASHIROVA
Antioch University Seattle
Seattle, WA

Placebo response has been an elusive phenomenon in the fields of medicine, medical
research, and psychology. Even though it has been heavily utilized as a comparator
treatment in double-blind psychopharmacological studies, the reliable definition and
consistent understanding of placebo response are missing. In this contextual exploration,
I outlined the state of current placebo response research and variable rates of placebo
response reported in double-blind studies. I identified the gap in the literature—lack of
consistent understanding of placebo response—that has led to a waste of resources by the
psychopharmacological research industry. Further, I compared and contrasted the current
inconsistent Western medical understanding of placebo as outlined by a leading expert on
placebo research (Fabrizio Benedetti) and the potential new understanding of placebo
response based on philosophical concepts of Hans-Georg Gadamer. I concluded that
placebo response appeared to be a contextual phenomenon and therefore could be
expected to behave similarly to other contextually based healing modalities as described
by Gadamer. I determined that the positivistic approach of modern medical research was
not an appropriate method for understanding, researching, or defining placebo. Thus, I
argued that psychopharmacological research could be improved by changing the way it
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used placebo in its control groups and maximizing placebo response in both placebo and
active treatment groups instead of minimizing it. I argued that this new approach would
bring the drug trial environment closer to the real life treatment environment and improve
the quality of the drug trials. The electronic version of this dissertation is at AURA:
Antioch University Repository and Archive, http://aura.antioch.edu/ and OhioLINK ETD
Center, https://etd.ohiolink.edu

Dedication
I dedicate this work to my mother who taught me to never settle and always try harder.
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Introduction to Placebo Response Understanding
Placebo response is an intriguing phenomenon that has been puzzling medical
doctors, psychiatrists, and psychologists alike for many centuries (Benedetti, 2009). It
has been both a nuisance and a welcome mystical phenomenon in modern science.
Despite numerous recent studies attempting to understand and explain how the
phenomenon occurs, lack of clarity persists in the definition of placebo response and in
understanding of its mechanisms of action (Benedetti, 2009).
Medical professionals had long been prescribing placebos with often positive
results for conditions that did not have a known etiology or cure (Walach & Jonas, 2004).
Moreover, Benedetti (2009) claimed that historically most medical interventions as well
as many interventions available currently had been relying mainly on the placebo effect,
because they did not contain any proven specific efficacious element otherwise:
Most, if not all, of these medicaments and procedures were based neither on
scientific rationale nor on the assessment of real efficacy, but rather they emerged
from metaphysical beliefs, social influences, and scientific ignorance about
anatomy and physiology related to that particular historical period. (Benedetti,
2009, p. 2)
Many such treatments included rather bizarre and odd concoctions of “skulls of victims
of violent death, frogs, worms, feathers, hair, horns, hoofs, ants, scorpions, viper flesh,
crab eyes, bee glue, fox lung, spider webs, teeth, sexual organs, and so forth” (Benedetti,
2009, p. 2). In modern medicine for example, many different antidepressants with
different neurological effects considered effective without a convincing unifying theory
that would explain why the neurological effects that they produce alleviate depression.
Not surprisingly, placebo response has produced a controversy in current pharmaceutical
and medical research. Understanding placebo response could both increase and diminish
the effect attributed to an active treatment (de la Fuente-Fernandez et al., 2001; Zubieta et
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al., 2005). This has happened due to the difficulties in the conceptualization of the
placebo response (Benedetti, 2009).
In this study, I looked more closely at this conceptualization predicament as it
applied to the area of research where placebo response is most utilized:
psychopharmacological studies. Indeed, pharmacological research is one of the few areas
in which placebo response has been actively used. Placebo response has been commonly
used as an inactive comparator in double- and single-blind studies. By utilizing this kind
of comparator group, pharmacological companies aspire to establish whether their newly
developed medications perform better than just the treatment routine alone (Benedetti,
2009).
In this case, the psychopharmacological researchers assume that the placebo arm
treatment group is equivalent to the active treatment in every way except for the active
ingredient exposure. The assumption here is that all of the cumulative improvement that
happens in the placebo group is due to the process of treatment (i.e., coming to research
clinic on a specific schedule, being assessed by doctors regularly, having one’s blood and
urine taken for chemical analyses, routine of taking pills as prescribed).
Benedetti (2009) suggested that this assumption described above might not be
warranted. In fact, he was quite critical of the pharmacological researchers lumping
together the spontaneous improvement, statistical regression to the mean, natural
progression of an illness, psychosocial factors, biases, and co-interventions that were not
accounted for properly (p. 5). According to the author’s conclusions, placebo response is
not a cumulative positive effect that a person experiences while in treatment. Instead, he
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suggested that placebo response is a phenomenon in its own right, separate from the
factors above.
Despite the pharmaceutical researchers’ many attempts to control the placebo
response via intricate study designs and controlling for the few identified contributing
factors such as patient-provider relationship and treatment environment (Benedetti, 2009,
p. 33), the response continues to fluctuate and has recently been on the rise (Benedetti,
2009; Bridge, Birmaher, Iyengar, Barbe, & Brent, 2009; Walsh, Seidman, Sysko, &
Gould, 2002). Walsh and colleagues conducted an analysis of published studies and
found a robust association between the year of publication and the response rate to
placebo in adult major depressive disorder trials. In their analysis of published studies,
Bridge et al. also found a significant correlation between the date of publication and
placebo response rate in children and adolescents. These findings suggest an increase of
placebo response over time. Increasing and out of control placebo response can
complicate interpretation of study results and, clearly, contributes to an increasing
number of so called “failed studies.” Failed studies are those whose results were
unsuccessful in producing clear separation of measured efficacy between placebo and
treatment groups. Currently, no reliable explanations exist for predicting and thus being
able to control placebo response (Benedetti, 2009). Researchers continue to explore the
phenomenon, but it is still difficult to grasp. Thus, its application in clinical work often
remains unpredictable.
The psychopharmaceutical industry has long been using the placebo response
phenomenon as a comparator treatment in their randomized trials (Benedetti, 2009). The
double-blind placebo-controlled study became a gold standard of the pharmacological
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research (Enck & Klosterhalfen, 2013; Relton, 2013). However, due to the lack of
knowledge about predictors of and factors influencing placebo response, the researchers
in the industry are not able to design studies in a way that protects from a large number of
failed and inconclusive studies resulting from unexpectedly high placebo response.
Comprehensive analysis of studies published by pharmacological companies
revealed a number of concerns (Song et al., 2010). Specifically, Song and colleagues
identified the tendency by the pharmacological companies to not publish studies whose
results were negative or inconclusive. Others also reported that this selective publishing
occurs (Turner, Matthews, Linardatos, Tell, & Rosenthal, 2008) despite the FDA
requirement to publish all of the results whether positive or negative (Prayle, Hurley, &
Smyth, 2012). This inevitably leads to a skewed understanding of efficacy of various
psychopharmacological products. Moreover, as also highlighted by Song et al., these
failed studies lead to a considerable waste of resources. This is particularly concerning to
consumers, as it is a common practice for businesses to push their increasing expenses
onto the consumer in a form of a higher price of their product.
Most importantly, however, thousands of studies conducted by the
psychopharmaceutical industry seem to contribute little to further the understanding of
placebo response. It is somewhat understandable, because psychopharmacological
companies are not in business to study placebo. They attempt only to study their own
products as “the main interest of both physicians and drug companies is to demonstrate
the efficacy of the therapy under test” (Benedetti, 2009, p. 9) not the limitations or
benefits of placebo. On the other hand, this tendency to ignore lack of understanding of
placebo appears somewhat irresponsible given that the industry has to rely on such a
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poorly understood phenomenon. The meta-analyses based on the psychopharmacological
studies data provide limited understanding of predictors of placebo response, as they can
look only at information collected by the studies (i.e., age, gender, length of trial, number
of visits, and severity of a diagnosis).
A main difficulty in identifying predictors of placebo response lies in the
theoretical weaknesses of placebo response conceptualization (Benedetti, 2009). The
researcher stated that clinical researchers conceptualize the placebo response as “any
improvement that may occur in the placebo group, regardless of whether it is a
spontaneous remission or a psychological phenomenon; whereas most psychologists
referred to the placebo response as: the psychological phenomenon that involves
expectations and anticipation of clinical improvement” (Benedetti, 2009, p. 5). The
author further considered that the placebo response is, in fact, “a context effect” (p. 34),
though through his descriptions it is evident that Benedetti still assumed that a specific
“baseline placebo” (p. 11) effect can eventually be identified. This is very much a
positivistic point of view, which assumes that one identifiable element, placebo response
in this case, can be pinpointed through a series of meticulous and targeted searches.
However, this theoretical approach has now been used for decades in placebo response
studies, and has been producing inconclusive and often contradictory results as the
current state of events shows (Benedetti, 2009; Enck & Klosterhalfen, 2013; Enck,
Klosterhalfen, Weimer, Horing, & Zipfel, 2011; van Haselen & Jütte, 2013).
In summary, it has been demonstrated that the psychopharmaceutical industry
tends to not publish their failed or inconclusive studies (Prayle et al., 2012; Song et al.,
2010; Turner et al., 2008). It is also known that placebo response in the double-blind
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studies has been on the rise and is contributing to the said failed and inconclusive studies
rate (Benedetti, 2009; Bridge et al., 2009; Song et al., 2010). I believe that the lack of a
firm and reliable understanding of placebo response is likely due to the inadequate
positivistic theory applied in describing this state-based phenomenon. A
conceptualization of placebo response from a theoretical point of view that accounts for
its contextual nuances is necessary to adequately describe the phenomenon and make it
applicable for research.
Purpose Statement
This study is a theoretical dissertation research exploring placebo response using
the philosophical arguments of Hans-Georg Gadamer (2004, 2011) as an alternative to
the currently accepted model in the medical field the positivistic approach illustrated by
the placebo conceptualization of Benedetti (2009). The purpose of this theoretical study
was to explore the understanding of placebo response from a contextual point of view in
an attempt to develop a better conceptualization of this phenomenon and broaden the
placebo phenomenon body of knowledge. Specifically, I explored placebo response as a
state-related and meaning-related phenomenon assuming that meaning is created through
cultural discourse. The understanding of placebo response through the work of Gadamer
was then compared to the current understanding of placebo by the medical community
presented via Benedetti’s work.
I completed a qualitative comparison of the differences between the two
theoretical conceptualizations and outlined the applicable implications for experimental
and clinical work with placebo. The main research question of this dissertation was as
follows: What are the differences between placebo response as it is understood by the
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mainstream Western medicine community and placebo response as it is understood by a
contextual theory of Gadamer’s hermeneutics? I believe that this alternative
understanding of placebo response would contribute to the general body of knowledge on
this subject. Additionally, since unpredictability and variability in strength of placebo
response lead to a waste of resources in the pharmacological research, resulting in
excessively highly priced pharmaceutical products, I hope with this research to augment
the current mainstream concept of placebo response to possibly help reduce this wasteful
trend in the future.
Contextual Theory Versus Trait Based Understanding of Placebo
In this section, I illustrated that a contextual theory is necessary to address some
of the common deficiencies of current placebo research. There is great variation in
placebo response from study to study and from condition to condition (Benedetti, 2009).
In line with positivistic thinking, placebo response studies and studies utilizing this effect
for comparison have assumed that placebo response is a trait-phenomenon and few
studies have actually marginally supported this idea (Bagby, Ryder, & Cristi, 2008;
Entsuah & Vinall, 2007; Grant, Kim, Hollander, & Potenza, 2008). Due to the
assumption that inherent (e.g., gender), historical (e.g., age), or present (e.g., current
diagnosis) traits are responsible for placebo response susceptibility, the studies that were
evaluating predictors of placebo response continued to search for correlations between
specific trait characteristics of subjects and their tendency to respond to placebo
positively (Benedetti, 2009).
Currently, psychopharmacological studies experience significant difficulty
controlling the rising placebo response (Benedetti, 2009; Bridge et al., 2009).
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Researchers appear to be attempting to control for the known trait and context related
variables affecting placebo response, but to no avail, as demonstrated by the number of
failed trials. Other scientists also confirmed that little could be gained from the current
studies involving placebo in understanding placebo response and individual factors
influencing it (Enck et al., 2011; van Haselen & Jütte, 2013).
Therefore, I showed in this work that a contextual theory could be used instead to
explore the elusive placebo response phenomenon. I conducted a qualitative exploration
of theoretical works by Hans-Georg Gadamer with an emphasis on the books The Enigma
of Health (2004) and Truth and Method (2011) to offer a contextual theoretical
conceptualization of placebo response. I believe that a qualitative comparison of the
differences between conceptualizations of placebo response, can advance theoretical
understanding of this powerful and elusive effect.
Why Gadamer’s Hermeneutics?
Hans-Georg Gadamer was one of the prominent philosophers of the 20th century.
His philosophy is most completely described in his seminal work Truth and Method,
originally published in German language in 1960. Though Gadamer did not directly
address the phenomenon of placebo response in his work, the principles for application of
his theory, hermeneutics, are clearly outlined in the most recent English translation of
Truth and Method (2011). Additionally, Gadamer dedicated a significant part of his
research career to understanding health, illness, and healing. The majority of his essays
on these topics are collected in the book The Enigma of Health (Gadamer, 2004). I
believe that Gadamer’s understanding of health, illness, and healing are indeed very
applicable to understanding placebos and placebo response.

9
I postulated that Gadamer’s hermeneutics provided the necessary theoretical
underpinning for understanding such a contextual phenomenon as placebo response. As
suggested by Richardson, Fowers, and Guignon (1999), Gadamer provided a way to
understanding not by giving a specific method to understanding, but describing where the
understanding takes place. According to hermeneutics, understanding is a dynamic
occurrence that depends on what is the context of the person who attempts to understand.
Hermeneutics originated as a form of religious text interpretation and an auxiliary
discipline in theology. Later, “the idea of general hermeneutics” has developed, which
applied “to all forms of human communication” (Richardson et al., 1999, p. 200).
However, at the turn of the 20th century, another shift has occurred in understanding
hermeneutics, which “reflected the growing awareness that devising rules for interpreting
humans is impossible and that the whole fascination with method is a by-product of the
very scientism being called in question” (Richardson et al., 1999, p. 200). Since then,
hermeneutics has been successfully used as a process and a philosophical foundation
from which to analyze and interpret “the being of the entities that interpret and
understand, namely, ourselves” (Richardson et al., 1999, p. 200).
Moreover, Gadamer’s (2004, 2011) hermeneutics provides specific constructive
criticisms of positivistic theories as they apply to natural sciences. I therefore have
directly applied his theoretical work to understanding placebo response as a phenomenon
in a natural science. Additionally, Gadamer’s work offers ways of understanding
phenomena as part of a socially constructed world where everything exists through being
defined linguistically, socially, culturally, and being situated historically. I hold that the
placebo response, as a contextual state-based phenomenon, is best conceptualized
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utilizing understanding of how linguistic, social, and historical aspects affect individuals
experiencing this phenomenon.
Summary
In this chapter, I demonstrated that placebo response is a puzzling phenomenon in
the fields of medicine, psychology, and clinical research. Part of what makes it difficult
to study is the lack of consistent definition, which would take into account the state-based
nature of this phenomenon. Despite the lack of understanding, placebo response is
heavily utilized by the psychopharmacological research industry as a comparator in their
double-blind studies. In last decades, the psychopharmacological industry has been
experiencing increased placebo response rate in studies, which led to failed trials and
waste of resources. Lack of proper placebo response definition appears to contribute to
the problem, because the drug research industry is unable to control the rising placebo
response rate in drug trials. I concluded that it was necessary to study placebo response
from a contextual point of view, because the current positivistic approach to
understanding placebo has not been successful. I proposed that Gadamer’s (2004, 2011)
hermeneutics—a contextual philosophical theory—would be one of the perspectives from
which to explore placebo response and compare it to current scientific, albeit
inconsistent, understanding of placebo response represented by Benedetti (2009, 2013)
(one of the lead scientists in placebo research).
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Literature Review
Narrowing the Scope of the Study
The purpose of this dissertation was to explore further my ongoing interest in the
study of placebo response that began almost a decade ago in an undergraduate
psychology class. This fascinating phenomenon intrigued me particularly with how
widely it spread over almost all areas of human physiological and mental functioning.
This remarkable connection between mind and body was impossible for me to ignore. I
later pursued a career in psychopharmacological research, which gave me firsthand
experience of how people respond to placebo in a single- and double-blind placebocontrolled study setting.
In over five years of coordinating Phase II, III and IV psychopharmacological
trials and seeing placebo response occur in humans, my curiosity about placebo response
transformed into a strong belief that humans can heal their mental disorders separately
from direct medication effects. I have seen depressed, anxious, and hypertensive people
taking a “dummy” pill become remarkably better in a matter of days. What made them
improve? Placebo response mechanisms are clearly not sufficiently understood
(Benedetti, 2009; Moerman, 2000).
The psychopharmacological research industry warns its research investigators and
clinical staff of harmful effects of high placebo response that can ruin years of research
and waste millions of dollars due to a “failed” trial. The industry is interested in learning
how to minimize placebo response in double-blind trials and to stop wasting so many
resources on “failed” trials, but seemingly has reached an impasse on how to achieve that
and it just continues to do more of the same (i.e., minimize contact with patients, avoid
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excessive niceness and friendliness, only accept people in the study with a severe enough
level of a disorder, etc.).
Defining placebo response. A positive change in a patient’s condition following
administration of a substance or a device that is known to be inactive is what is usually
called placebo effect (Walach & Jonas, 2004; Zubieta et al., 2005). Correspondingly, a
negative change in response to an inert substance or device is often called nocebo (Enck,
Benedetti, & Schedlowski, 2008). Active and inert/inactive placebos are currently
identified in research and medicine where active placebos produce some specific
measurable effects in the body, but the effects cannot be directly attributed to the
expected changes in the body. The scope of this dissertation is limited to the effects of
inactive placebos. See Definitions section in Methodology and Delimitations for
definitions of active and inactive placebo and nocebo effects.
In previous decades, a number of different kinds of changes like “spontaneous
remission, measurement artifacts, and regression to the mean” (Walach & Jonas, 2004,
p. S-103) have been lumped under the phenomenon of placebo effect by confused and
careless writers (Benedetti, 2009; Walach & Jonas, 2004). This lead many researchers,
who used placebo as their control group in studies of pharmacological and other
treatments, to assume that placebo effect is the average improvement in their placebo
arms. However, I believe that the most helpful way of describing placebo response, as
Walach and Jonas suggest, is to specifically define it as “self-healing capacities of a
person” because research studies conducted with human subjects are unable to control for
all other possible artifacts that contribute to improvement.
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Current Knowledge and Understanding of Placebo Response
Currently, the psychopharmacological research industry attempts to reduce
placebo response through some logical steps: asking investigators and study staff to
reduce chatting with patients beyond common courtesy and medical necessity, create
studies that call for fewer procedures (i.e., less time spent with study doctor and staff in
the clinic), begin studies with a single-blind placebo, and eliminate responders prior to
having them start study drug treatment. However, there are no specific studies that
support these steps as being effective placebo response prevention/reduction measures.
On the contrary, an overview article by Moerman (2000) showed a tendency for studies
with more visits (i.e., more contact with study doctor and study staff) to show a smaller
placebo response rate.
Experience of placebo response. In the substudy of a larger double-blind trial
that explored acupuncture treatment for irritable bowel syndrome (IBS), Kaptchuk with
colleagues (2009) interviewed 12 patients who were assigned to a placebo arm of the
study. They were able to reveal the double-blind treatment assignment to their subjects
after the main study was completed. Participants ranging in age from 23 to 65 were
interviewed a few times during the main study while on their assigned treatment. They
were also interviewed during post-study briefing after the treatment code was revealed to
them.
They found that most placebo arm participants found their study treatment to be
beneficial and reported moderate to dramatic improvement in their IBS symptoms.
Additionally, when asked about their thoughts on placebo treatment, participants revealed
a clear understanding of placebo was and what treatment with placebo meant. During the
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treatment phase of the study, most participants also shared that they thought about the
possibility of being assigned to the placebo arm and tried to determine whether they were
assigned to the placebo or the treatment arm. Participants reported carefully observing
the manipulations of their study acupuncturists, paying attention to how the needles felt
when applied to their skin, and noticing any variations in their IBS symptoms while
trying to identify the most likely cause for those variations.
These findings showed that participants assigned to the placebo treatment were
thinking critically throughout the process and spent considerable time trying to figure out
through personal observations whether they were on placebo. Additionally, Kaptchuk et
al. (2009) found that many of the participants were questioning their improvement during
the study and wondering if it was a treatment effect, a normal variation in their IBS
symptoms, or if their minds were “tricking” them into feeling better. Overall, by the end
of the study, most of the participants who responded to placebo believed that they were
assigned to a real treatment, not a placebo (Kaptchuk et al., 2009). One participant even
refused to accept that she was given the placebo treatment during study, because her
improvement was so significant and because her personal observations led her to believe
that she was on a real acupuncture treatment.
The study by Kaptchuk et al. (2009) showed the complexity of placebo response
as it might be experienced by humans. Most of the participants assigned to the placebo
arm (except for the woman who refused to believe that she was on placebo) were
surprised to learn about this assignment, but during the briefing found a way to
understand and explain it. Such explanations included beliefs that IBS has a lot more to
do with mental activity than they realized, that placebo acupuncture could also be a good
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treatment, etc. The study also showed how real the effects of placebo can be to those
experiencing them and that they could constitute a real treatment for some rather than
being a nuisance variable.
Mechanism of placebo response. It is not surprising that participants found
placebo treatment so tangible. As shown in Benedetti, Mayberg, Wager, Stohler, and
Zubieta (2005) overview, placebo response mimicked the same neurological mechanisms
as an active treatment. Moreover, in some cases placebo response was more precise at
targeting only areas of the brain responsible for the main effect and not causing additional
side effects. Benedetti et al. did not make any speculations regarding how various trait
characteristics of a subject could influence suggestibility, expectation, or conditioning.
Wager et al. (2004) showed that placebo analgesia produced brain activity changes in
anticipation of pain rather than changing the experience of pain as it occurred. Again,
this study was not making any predictions or speculations regarding trait-based
characteristic differences in such anticipation effects.
Additionally, placebo response, though naturally associated with mental activity
and therefore expected to be more prominent in more brain-related disorders, actually
appeared in treatment of less mind-linked conditions (Kemeny et al., 2007; Shetty,
Friedman, Kieburtz, Marshall, & Oakes, 1999). Researchers found a significant placebo
response in the double-blind pharmacological treatment of asthma symptoms (Kemeny et
al., 2007). The reported placebo response in this study was conservatively measured at
18% of participants responding to placebo with significantly reduced bronchial
hyperreactivity compared with baseline.
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In studying children, Goodenough et al. (1997) found that placebo cream
application prior to venipuncture did not produce a significant placebo response. In their
randomized controlled trial of three groups of children varying in age from 3 years and 5
months to 17 years and 7 months, researchers found no significant differences in reported
amount of pain following a venipuncture. Additionally, they did not find any significant
age or sex correlation and the amount of pain reported. The significant predictors of pain
were only prediction of pain by participants (i.e., when participants predicted that the
venipuncture would hurt, they were more likely to actually experience pain) and whether
a person was a “looker” versus not a “looker” (e.g., not looking at the needle during
venipuncture). The results of this study were not conclusive and should be used with
caution, since the study failed to produce placebo response altogether. Moreover, it was
difficult to draw conclusions regarding age differences in placebo response since no
significant placebo response was observed.
Placebo response prevalence in double-blind studies. Placebo response in
depression studies has been rather considerable. Bridge et al. (2009) conducted a metaanalysis of 12 randomized controlled trials of pediatric double-blind pharmacological
treatment of major depressive disorder (MDD), where 2,862 patients were involved.
Ages of the participants ranged from 6 to 18 years old. The meta-analysis provided
information regarding the average placebo response in all of these trials and attempted to
find the predictors of placebo response in pediatric MDD trials. Researchers found that
on average 46% of participants who were assigned to placebo responded to it. This
response rate varied across studies from 34 to 58% responders to placebo, whereas from
48 to 70% of the participants were responders to antidepressant. Bridge et al. found that
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neither age nor sex were good predictors of placebo response. However, severity of
MDD was negatively correlated with placebo response. As follows from this large metaanalysis, children ages 6 to 18 participating in pediatric MDD double-blind studies
responded to placebo on average in 46% of cases and the more severe their MDD
symptoms the less likely they were to respond to placebo.
Unfortunately, in a similar meta-analysis of late-life depression treatment by
Sneed et al. (2008), the placebo response rates were not reported. Only antidepressant
response rates were reported, which ranged from 35 to 77%. It appeared that these
response rates in individuals over 60 years old were somewhat higher than in pediatric
trials. However, studies included in the late-life MDD meta-analysis by Sneed et al. also
included active comparator treatment studies, not only placebo-controlled studies.
Researchers stated that in the active comparator research designs, response to study
medication was higher than in the placebo-controlled designs (60% vs. 46% response rate
to study medication). Sneed at al. speculated that the difference in response due to study
design might be due to participants’ expectations, as they might be less likely to respond
positively to a treatment when a chance of being on placebo was present.
In IBS syndrome, double-blind studies showed a more varied tendency.
Specifically, Patel et al. (2005) in their meta-analysis of randomized controlled doubleblind pharmacological treatments of IBS found that placebo response ranged from 16 to
71% of people improved while on placebo. Though on average it was similar to a
placebo response in pediatric MDD trials at 40.2%, it varied much more and was
dependent on the number of office visits. Patel with colleagues found that with each
additional visit at the research office for treatment, a reduction in placebo response was
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observed by 4.4%. Notably, Patel et al. also observed the lack of consistency across
studies in definition of response for both placebo response and active treatment response:
The definition of a global response varied widely among studies, ranging from
binary to continuous variables. Some trials recorded ‘improvement vs no
improvement’ whereas others evaluated the Subject’s Global Assessment of
Relief (SGAR) with a predefined scale that characterized response to treatment. In
our study, ‘responders’ were patients who showed a global response according to
the study’s definition, or, in studies lacking a global response definition, patients
who showed global improvement in symptoms. (p. 333)
Diversity in placebo response. Few studies reported differences in placebo
response across cultures. A literature review conducted by Moerman (2000) provided
some information on such variations. As reported by the researcher, differences existed
in placebo response rates between ulcer disease double-blind studies conducted in
Germany and Brazil. The German participants in Germany tended to have higher
placebo response compared to their Brazilian counterparts in Brazil.
Additionally, such aspects as culture-specific response to size, color, and shape
influenced treatment response (Moerman, 2000). For instance, branding of a medication
pill and coloring it culturally expected color increased the medication potency (p. 54).
Specifically, a Dutch study showed that “cool” colors like blue (a culture-dependent
perception) were used more for depressants and “hot” colors like red or orange for
stimulants (de Craen, Roos, de Vries, & Kleijnen, 1996). Moerman made a side note that
“[c]olor and form are not invariably this clear: Viagra, for example, is marketed in a blue
tablet” (p. 66). I speculate that the light blue color of Viagra may be explained if it is
meant to represent the maleness (i.e., baby blue stands for male and manhood in Western
culture).
Cultural aspects may also play into the notion of nocebo which has the opposite
effects of placebo (i.e., making someone’s condition regress due to some external factors
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or due to taking an inactive substance). Moerman (2000) provided an example of
Chinese Americans affected by chronic diseases having lower life expectancy than their
White American counterparts with the same disease do if according to their belief system
the year of their birth made them susceptible to the disease in question. It provides an
excellent example of how powerful one’s beliefs may be and how that may affect one’s
treatment in general.
Furthermore, Moerman (2000) urged researchers to not misinterpret the data from
placebo-controlled trials or trials where “no treatment” was the treatment. If a condition
appeared to resolve “on its own” during a “no treatment” observational trial, one could
not definitively state that the condition did not require treatment. Instead, the conditions
under which the patient was observed should be considered the effective treatment.
Coming to a doctor’s office, receiving a physical exam, and being interviewed by a
doctor regarding symptoms might be just as potent as a pill. However, if a study
concluded that one did not require active treatment to heal, those suffering from the
disorder would be unlikely to experience the “no treatment” conditions as they might not
be seen at all, and instead be advised to wait and let the condition resolve on its own.
Walach, Sadaghiani, Dehm, and Bierman (2005) also agreed that conditions under which
participants were treated account for a great proportion of treatment success in the
double-blind trials. This also highlights the importance of examining contextual
variables in placebo research.
Open-label placebo. Sandler, Glesne, and Geller (2008) conducted a sub-study in
an open-label (vs. blinded) randomized pharmaceutical trial of dose extension of child
Attention Deficit/Hyperactivity Disorder medication. Children and their parents in a
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placebo group (who were aware that they were in a placebo group) were interviewed
(open-ended questions, one 20–30 minute interview) about their 3-month experience on a
placebo extender (taken mid-day in addition to a morning dose of an actual stimulant
medication). Curiously, researchers found that most (75%) of the participants found the
experience positive and beneficial. They found that patients and their parents found
taking it beneficial at least to some degree, even when aware of being in a placebo arm
and having a clear understanding of what placebo was. One child participant described
the placebo pill as an “extension of his medicine” regimen and after a while thought of it
as part of a treatment, not a dummy pill.
Suggestibility (“Suggestibility,” n.d.) explanation of placebo response assumes
that a patient is, in a sense, fooled by a doctor or a researcher into believing that the
treatment they are receiving is going to be beneficial for them. The findings of the
Sandler et al.’s phenomenological study (2008) made the positivistic definition of
suggestibility rather questionable, since patients were acutely aware of the sham nature of
the placebo treatment they received and were not fooled.
More Positivistic Explorations of Placebo Response
The first documented successful attempt to describe how placebo response might
manifest itself on a neurological level was done by Levine, Gordon, and Fields (1978).
They discovered that analgesic effects of placebo could be reversed by administering the
opioid-blocking substance naloxone. This blocking effect was assumed to occur in a
similar manner to how morphine analgesic effects were reversed by naloxone and it led
the scientists to believe that placebo analgesia must work on the same neural pathways as
opioids. This discovery triggered a long line of successive research exploring the
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analgesic properties and pathways of placebo (Kong et al., 2006; Petrovic, Kalso,
Peterson, & Ingvar, 2002; Wager et al., 2004; Zubieta et al., 2005).
With the help of modern technology, it became a lot easier to study the
neurological bases of placebo response in analgesia and a number of other conditions. In
fact, Levine and colleagues’ original hypothesis (1978) of opioid pathways activation by
placebo was verified and expanded by a number of recent studies using positron emission
tomography (PET) scans and functional magnetic resonance imaging (fMRI) (Kong et
al., 2006; Petrovic et al., 2002; Wager et al., 2004; Zubieta et al., 2005). Moreover, the
analgesic placebo effect was one of the most widely studied phenomena, possibly due to
the fact that the analgesic effects could be quickly seen and easily measured (Benedetti et
al., 2005; Kong et al., 2006). These new technologies provide an important insight into
how placebo response takes place in the human brain.
More specifically, Petrovic et al. (2002) discovered using PET scans that
analgesic effects of placebo in a heat-induced pain response activated similar areas as
opioids did. Surprisingly, the reduction in pain after administration of placebo was
reported by all subjects in this study, though it varied considerably interindividually. The
specific areas the researchers found activating in both opioid-induced and placeboinduced analgesia were in the rostral anterior cingulate cortex (rACC) and brainstem.
The effects of the placebo were much more specific and did not affect as many cortical
and subcortical areas as an opioid administered in this study. The main effect of
remifentanil, the opioid analgesic used in this study, was the significantly increased
activity bilaterally in both rostral and caudal anterior cingulate cortex (ACC) (extending
also to ventromedial prefrontal cortex), insula, orbitofrontal cortex (OFC) (extending into
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the temporopolar areas), and lower pons. The effect was defined as PET-captured
activity with pain administration minus PET-captured activity without pain
administration. This effect was especially prevalent in the rACC and in the anterior
insula. This activity was imitated by the brain during placebo administration, though to a
much lesser degree. The increased activity was found in the OFC regions bilaterally, but
mainly in the right hemisphere and the contralateral rACC (the pain stimulus was applied
to the left hand of right-handed participants) (Petrovic et al., 2002). Most importantly,
the areas that overlapped in both the opioid and the placebo analgesia network were OFC
in the right hemisphere and rACC.
It was shown that in general caudal ACC was activated during pain and
unpleasantness, but rACC was activated in conditions involving suggestion and resulted
in modulation of pain. One of the post-hoc findings by Petrovic et al. (2002) was that
high placebo responders had rACC activation in response to pain while low responders
did not. This made a strong case for viewing rACC as an area involved in modulation of
pain experience. Petrovic and colleagues further suggested that placebo responders might
have a more efficient opioid system. Additionally, it was speculated that brainstem
activation (pons area specifically) was produced by the higher cortical systems. This
activation happened during both opioid and placebo analgesia effect.
Wager and colleagues (2004) aspired to understand whether placebo-induced
analgesia was achieved via altering pain transmission, changing pain affect, or by
producing compliance with suggestion of investigators. They conducted two fMRI
studies and concluded that placebo did not numb the pain, but instead changed the
experience of it. Their major finding was that both dorsolateral prefrontal cortex (PFC)
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and OFC activation correlated with midbrain activation during pain anticipation after
placebo administration, consistent with the idea that prefrontal mechanisms trigger opioid
release in the midbrain. Wager et al. (2004) agreed that “OFC and midbrain regions are
not typically associated with directed attention” (p. 1166). However, they speculated,
“activation of these regions seems more consistent with the view that anticipation during
placebo involves a specific expectancy process that may be related to opioid system
activation” (p. 1166). This important finding opened another window into placeboinduced analgesia—it seemed to change the experience of pain by anticipating pain
experience and activating specific brain regions getting ready for the experience.
A study by Kong et al. (2006) used fMRI scans and sham acupuncture needles to
test their hypotheses regarding the neurobiology of placebo analgesia. The pain stimulus
in this study was administered to the right hand of the right-handed participants. The
activation was seen in the bilateral lateral/OFC, rACC, cerebellum, right fusiform,
parahippocampus, and pons. Most importantly, it was found that placebo analgesia was
positively correlated with the activity in rACC even in a study with a different analgesic
paradigm (acupuncture worked on different analgesic mechanisms than opioids). The
more strongly subjects exhibited placebo-induced analgesia, the more activated were
their rACC. Therefore, the hypothesis regarding rACC mediating pain in suggestion
scenarios was once again supported with this study.
Additional information regarding placebo analgesia pathways was gained by
Zubieta et al. (2005). They used PET to examine the activation of μ-opioid receptors in
sustained pain with and without placebo administration. Their findings suggested that
placebo activated both higher-order and sub-cortical brain regions like rACC,
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dorsolateral PFC, insula, and nucleus accumbens. They found significant differences
across their subjects in activation of these areas, but overall their results supported the
previous findings where rACC, PFC, and insula were involved in placebo-induced
analgesia. It was now shown, however, that μ-opioid receptors specifically were
involved in producing the analgesic effect.
Placebo for Parkinson’s disease and depression. Interestingly, placebo
response in relieving Parkinson’s disease symptoms was also found to be very prominent
and was often used in research (Benedetti et al., 2004; de la Fuente-Fernandez et al.,
2001). The neurobiology of placebo response in patients with Parkinson’s is quite
different from neurobiology of placebo-induced analgesia. As hypothesized by the
researchers in their study (de la Fuente-Fernandez et al., 2001), “the placebo effect is
mediated through the activation of the pathway relevant to the disorder under study”
(p. 1164).
In their PET experiment, de la Fuente-Fernandez and colleagues (2001)
discovered significant changes in the caudate nucleus and the putamen with greater
changes seen in the posterolateral part of the putamen. These changes (increases in
dopamine availability) were comparable to the effects of therapeutic dose of levodopa.
Consequently, “placebo-induced release of endogenous dopamine in the striatum”
(p. 1164) was observed and this finding was consistent with current etiology theory of
Parkinson’s disease. Placebo seemed to be working on the same networks as active
medication to relieve symptoms of Parkinson’s. Similar results were found by Benedetti
et al. (2004). The researchers also tested a hypothesis regarding use of placebo as a
control in medication trials and concluded that at least in some patients most of the
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benefit obtained from an active drug might derive from placebo response (de la FuenteFernandez et al., 2001).
Moreover, placebo response could be seen on neurological levels not only
immediately following placebo administration, as in pain and in Parkinson’s research, but
also in a more long-term placebo administration. A 6-week double-blind trial for
depression that used a placebo control group and an active-medication (fluoxetine) group
utilized PET to look at changes following the treatment period (Mayberg et al., 2002).
The researchers discovered a common pattern in cortical and subcortical regions
activation that was close to identical in both placebo-responders and fluoxetineresponders. They found that placebo-responders specifically had increased metabolic
activity in neocortical and limbic-paralimbic regions with significant increases in PFC,
premotor cortex, inferior parietal cortex, posterior insula, and posterior cingulate.
Additionally, researchers saw a statistically significant decrease in metabolism in
subgenual cingulate, hypothalamus, thalamus, supplementary sensory area, insula and
parahippocampus. Responders to fluoxetine showed additional changes in metabolism in
subcortical and limbic regions and more specifically in striatum, hippocampus, and
anterior insula.
The studies of placebo use in pain modulation, Parkinson’s symptoms relief, and
depressive symptoms relief showed that there was no placebo-specific pathway in the
brain that produced general placebo response (Enck et al., 2008). Each placebo response
pathway was expectation-specific and worked in ways very similar to the ones active
medications used. Expectation and Pavlovian conditioning were suspected to be at work
mediating these processes (Benedetti et al., 2005; Walach & Jonas, 2004).
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One of the hypotheses of placebo response was that an expectation network
activated in the brain. The expectation network when activated was responsible for the
experience. The expectation was triggered by the investigator/doctor suggestion,
previous knowledge, or classical (Pavlovian) conditioning.
Understanding and implementing placebo response. The results of the
neuroimaging studies of placebo responses and psychotherapy effects suggested that
“beliefs and expectations can markedly modulate neurophysiological and neurochemical
activity in brain regions involved in perception, movement, pain, and various aspects of
emotional processing” (Beauregard, 2007). Based on the imaging evidence presented
above, it is now known that direct physical or biological/chemically-active intervention is
not required to produce significant and specific changes in the brain. Therefore, by using
information gained from placebo and other non-biological interventions, psychologists
and medical doctors might be able to deliver more appropriate care to their patients: the
care that harnesses the natural healing capacities of humans (Stefano, Fricchione,
Slingsby, & Benson, 2001; Walach & Jonas, 2004).
Further Research
There is a lot to learn about this phenomenon of “self-healing” (Walach & Jonas,
2004). For instance, it is yet to be determined if placebo response mediated by
suggestion is different from placebo response that is explained by classical conditioning
(Enck et al., 2008). Additionally, Brody and Brody (2000) suggested that
multidisciplinary research was needed to integrate qualitative measures of meaning and
perception with quantitative measures of biochemical mediators. Such research would
allow scientists to better predict how well someone would respond to placebo and
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possibly to an active treatment, as “meaning has biological consequences” (Moerman &
Jonas, 2002).
Meaning assigned to treatment by a patient in a conscious way does not always
explain the placebo response phenomenon. For instance, placebo response seen in
immune, hormone, and respiratory systems seemed to be occurring as a subconscious
classical conditioning process rather than a conscious expectation (Price, Finniss, &
Benedetti, 2008). However, Moerman and Jonas (2002) were discussing the meaning
and meaning-making in the hermeneutic sense, where subconscious processes took part
by manifesting the values and beliefs of the cultural-historical context in which patients
existed.
Summary of Positivistic Research and Implications
Thanks to neurocognitive research, more is now known about the illusive
phenomenon of placebo response and it now appears more measureable (Benedetti et al.,
2005; Price et al., 2008). Placebo response in double-blind pharmacological studies tends
to vary greatly from study to study, but on average remains around 40 to 46%. The
condition for which one receives treatment also determines the placebo response. For
instance, in treatment of pediatric MDD, placebo response ranged from 34 to 58%—the
percentage of individuals in the placebo groups who scored ≤2 on the improvement item
of the Clinical Global Impression scale (Bridge et al., 2009), whereas in treatment of
ulcers the range of placebo response was from 0 to 100%, which was measured by
percentage of people in the placebo groups who had “endoscopically observed healed
ulcer craters” (Moerman, 2000, p. 58). It appears that studies of placebo response are
difficult to conduct and often hard to interpret.
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Placebo response is still often considered an unexplained side effect by the
general public and primary care physicians (Brody & Brody, 2000). The response is
discarded as not attributable to a “real” intervention and thus as not a “real” effect.
However, the effects produced by placebo through suggestion, expectation, and
Pavlovian conditioning are visible and measurable on neurobiological level using the
modern technology. Nonetheless, the above studies continue to be restricted by the same
limitations that are inherent in using positivistic theory: inherent reductionism of
positivistic studies is often insufficient to describe and explain complex systems. Placebo
response phenomenon, I believe, is a complex system and requires a different approach
for studying it.
Contextual Explorations of Placebo Response
A contextual exploration is a method of annotation, which takes into account
context. So far, very few studies have attempted to look at placebo response using a
contextual theory. A contextual theory would attempt to understand placebo response as
a phenomenon that exists within a set of circumstances surrounding it rather than a
phenomenon that is interrupted or contaminated by contextual variables. Thompson,
Ritenbaugh, and Nichter (2009) proposed an anthropological conceptualization of
placebo where the “whole systems” approach was taken to the healing (p. 139). In many
ways, the authors provided an important reconceptualization of placebo response as a full
range human experience as it is located socially, culturally, and linguistically. They also
brought out the important aspect of discourse when it came to understanding placebo as
an underresearched topic. They identified that placebo response conceptualization in
literature overly relied on conscious cognitive approaches rather than direct embodied
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experience common in meaning-making of healing. The researchers believed that by
taking a more holistic approach to understanding placebo, one might better understand its
healing qualities. Unfortunately, Thompson and colleagues did not suggest what
implications their conceptualization could have on current double-blind study designs.
Summary
In this chapter, I provided an overview of current state of research on placebo
response. Majority of placebo research in the literature is of quantitative positivistic type.
I began the chapter with describing my personal interest in placebo response and its direct
connection with drug research. I narrowed the scope of this study to placebo response
and its use in psychopharmacological industry. I provided examples of placebo response
experience by study participants. These examples showed how real that experience of
healing from illnesses felt to them.
I highlighted that in recent decades neurocognitive research, had helped to make
placebo response more measureable. However, placebo response had remained
unpredictable and varied across studies of various conditions and age groups. It appeared
to me that studies of placebo response were difficult to conduct and their findings were
just as difficult for researchers to interpret. I concluded that the inconsistencies found in
studying placebo response contributed to dismissal of the phenomenon as something
made up and unproven. Yet, the effects produced by placebo were visible and
measurable on neurobiological level using modern technologies. The literature review
highlighted the need for an alternative understanding of placebo response to counteract
the inherent reductionism of positivistic empirical studies and to help explain a complex
system (placebo response).
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Methodology and Delimitations
Research Questions
The following are the questions I intended to answer with this study. What are the
differences between placebo response as it is understood by the mainstream Western
medicine community and placebo response as it is understood by a contextual theory of
Gadamer’s hermeneutics? How could these differences inform the
psychopharmacological double-blind study design?
Research Approach
A hermeneutic exploration using Gadamer texts and observation of modern
culture were used as primary ways to identifying aspects of placebo response as a
contextual phenomenon. Then contextual definition of placebo response was discussed.
The new definition of placebo response was applied to the double-blind
psychopharmacological trials, and derived implications were recorded.
Delimitations of the Study
The topic of placebo response is very vast. It is a phenomenon that is manifesting
in various aspects of healing such as psychotherapy, treatment of medical conditions, as
well as in performance on cognitive and physical tasks (Benedetti, 2009). To delimit the
study and identify the scope of this research, only placebo response as used in
psychopharmacological trials was explored for application of this theoretical treatise.
Possibly, similar contextual perspective might need to be taken when identifying placebo
response in other areas of healing listed above. However, the identified purpose of this
study was to illuminate the differences between the positivistic approaches in defining
placebo response and Gadamer’s (2004, 2011) hermeneutical understanding as applied to
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the psychopharmacological studies. Psychopharmacological research industry
historically had used placebo response phenomenon and had been relying on it most
heavily in the scientific study of psychopharmacology.
I used the work of Fabrizio Benedetti (2009, 2013), an Italian researcher
specializing in studying placebo response phenomenon, as the primary source that
represented Western medicine’s point of view. The reason for this choice was Dr.
Benedetti’s worldwide recognition as an authority on the subject of placebo response.
Since mid-1990s, he authored and coauthored numerous research articles exploring the
extent of placebo response (Benedetti, n.d.). Benedetti, one of the major researchers of
this phenomenon, brought together research from various subfields of science (such as
medicine, psychology, and pharmacology) in an attempt to streamline and define placebo
response, while he highlighted inconsistencies across the subfields.
For the contextual point of view, I used hermeneutics as a base from which to
describe a contextual phenomenon as well as to critique the modern Western medicine’s
empirical point to view. Hermeneutics, although comparable to other interpretive
theories such as discursive, constructionist, and dialogical theory, had been used
specifically to provide an alternative to empirical, scientific research methods in
psychology and medicine (Kirschner & Martin, 2010). It challenges core positivistic
assumptions of modern psychology and medicine research. I used Gadamer’s
hermeneutics as a lens through which to assess placebo response phenomenon.
Gadamer’s work is known for its extensive critique of human sciences in modern
research. He specifically argued against using natural science model for human sciences.
Additionally, Gadamer greatly contributed to the hermeneutic literature with his writings
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on modern medicine and the ideas of illness, health, and healing. I considered his work
critical to the hermeneutical exploration of placebo response. Thus, I based my
theoretical exploration of placebo response primarily on Gadamer’s hermeneutics.
Definitions
Active comparator is a medication whose efficacy for a specific condition is
already established and it is being used in a double-blind research design as a comparator
to a study medication.
Active treatment, in the context of pharmacological treatments research, refers to
a pharmacological intervention that has known pharmacological effects of therapeutic
value.
Active placebo is a chemical compound used in pharmacological research that
produces some felt physiological response that is not by itself found to be therapeutic, but
mimics the side effects of the treatment under test (Benedetti, 2009, p. 7).
Inactive placebo is a chemical compound used in pharmacological research that is
commonly referred to as “sugar pill” and does not necessarily contain any sugar or
possess any ability to produce therapeutic effects in a living organism for the condition
under study.
Double-blind treatment, in the context of pharmacological research, refers to an
active or placebo treatment that is hidden from both the participant and the researcher.
Neither of them knows during study whether the participant is taking an active
medication or a placebo.
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Nocebo is the term which was introduced in contrast to the term placebo (‘I shall
harm’ vs. the classical Latin meaning of placebo: ‘I shall please’) by some authors to
distinguish the pleasing from the noxious effects of placebos (Benedetti, 2009, p. 35).
Nocebo response or nocebo effect is a negative response associated with an inert
treatment that does not possess any therapeutic and/or toxic properties. In this negative
response, negative context and/or verbal suggestions of clinical worsening prompt the
negative expectations about the outcome (Benedetti, 2009, p. 35).
Open label treatment, in the context of pharmacological research, refers to an
active or placebo treatment, where the nature of this treatment is known to (i.e., not
hidden from) the research participant as well as to the researcher administering the
treatment. In an open-label treatment, the participant and the researcher both know what
exactly the participant is prescribed during the study.
Placebo response/placebo effect—the definition of placebo response applied
throughout this study is that explained by Benedetti (2009, 2013) for clinical research—it
constitutes an improvement in someone who has taken placebo, and the improvement is
due to either regression to the mean, spontaneous remission, or a body’s natural ability to
heal itself via some not yet identified mechanism. See a more extensive discussion about
placebo response definition in Definition Confusion subsection of this chapter.
Regression to the mean is a phenomenon in pharmacological studies where the
condition under study reduces in severity not due to a treatment, but because of the nature
of all conditions to go up and down in severity. If participants’ severity of the condition
was measured during the exacerbation of the condition, it is expected that when the
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severity of the condition is measured again it will likely be lower as it would go down to
its average, or mean, rate of severity.
Definition confusion. As previously stated in the Delimitations section, only
placebo response within a context of psychopharmacological double-blind placebocontrolled studies is discussed in this study. Thus, the psychopharmacological industry’s
global understanding of placebo response is employed in this research. Placebo response
and placebo effect are interchangeable terms describing the improvement in a placebo
group (also known as a group that received placebo treatment during study) due to either
regression to the mean, spontaneous remission, or a body’s natural ability to heal itself
via some not yet identified mechanism.
As summarized by Benedetti (2009), the term placebo effect brings confusion into
science, which “resides in the fact that the improvements that may take place in patients
who receive placebo may be due to many factors, for example spontaneous remission or
expectation of therapeutic benefit or other factors” (p. 5). Other researchers have
observed that in clinical research, improvement in placebo groups regardless of the
reason is attributed to placebo effect. However, psychologists typically refer to placebo
effect as a psychological phenomenon associated with expectation of improvement (p. 5).
Moreover, Hoffman, Harrington, and Fields (2005) proposed to discriminate between the
terms placebo response and placebo effect by using the word response to define the
psychological phenomenon and the word effect to refer to the global outcome in the
placebo group. More about the differentiation between response and effect of placebo is
discussed in Suggestions for Future Research. Even though Benedetti (2009) stated,
“placebo effect, or placebo response, is a psychobiological phenomenon that must not be
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confounded by other phenomena, such as spontaneous remission and statistical regression
to the mean” (p. 19), the clinical research industry does not clearly define placebo
response. In fact, spontaneous remission, regression to the mean, the natural history of a
disease, as well as “expectation-modulated anxiety, expectation of reward, learningreinforced expectations, social learning, Pavlovian conditioning, personality traits,
genetics” (Benedetti, 2013, p. 1220) together constitute the placebo response category for
clinical trial purposes. Therefore, for the purposes of this study, a placebo response
constitutes an improvement in someone who has taken a placebo, and the improvement is
due to either regression to the mean, spontaneous remission, or a body’s natural ability to
heal itself via some not yet identified mechanism.
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Healing in the Modern World
As I illustrated in the Literature Review, until now, placebo response has been
studied mostly as a natural science phenomenon. In this chapter, I provide a case for
placebo response being a phenomenon to be studied by human sciences. I begin with
illustrating that health, illness, and treatment are important parts of Western culture. I
then provide a summary of Gadamer’s (2004, 2011) understanding of health, illness, and
treatment from hermeneutic point of view. Hermeneutically, treatment is understood as a
process of restoration to health, which is affected by cultural-historical influences. Using
Gadamer’s hermeneutics, I provide a critique of natural science being used for describing
human phenomena. I outline a summary of Benedetti’s (2009, 2013) understanding of
placebo response and compare them to Gadamer’s understanding of treatment. I
conclude that placebo phenomenon appears to be a subject to be studied by human
sciences.
Health, Healthy, and Healing as Part of Social Discourse
The conversation about health, healthy, and healing techniques and procedures
dominates the social discourse. This preoccupation with health and healing is evident
any time one is exposed to the media: internet sites, popular and scientific literature,
newspapers, magazines, television programs, and radio broadcasts are full of information
about healthy practices, new illnesses, and new treatment methods. The methods
discussed may be either carefully researched or carried over from traditional healing
practices.
Food, clothing, household and hygiene products, dishware, and furniture are
covered with labels that appeal to the current ideas of what is healthy. Labels like
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“organic,” “locally-grown,” “natural,” “does not contain [list whatever the unhealthy
contaminant of the day here]” are found in abundance any time one opens one’s pantry or
walks into a supermarket. The marketing techniques in capitalist society end up telling
quite a bit about the values the society currently holds. Thus, observation of the
marketing messages in modern Western society clearly illuminates the value it places on
health and healing.
What Is Health and What Is Illness?
To have a conversation about placebo and placebo response, it is important to
identify what constitutes health and illness. As discussed earlier in this paper, placebo
response is defined as an improvement in a placebo group due to either regression to the
mean, spontaneous remission, or a body’s natural ability to heal itself via some not yet
identified mechanism. One would need to know what constitutes illness and what
constitutes health to know how the placebo response might be helping humans to go from
one condition to the other.
Gadamer’s View
In The Enigma of Health (2004), Gadamer provided a hermeneutic
understanding of modern medical practice and healing practices in general. His work is a
philosophical account of the meaning of healing. He described the embeddedness of
healing practices in modern Western culture. Hermeneutics concedes the idea that there
is meaning-making behind all human communications and practices. Thus, illness and
methods of healing should carry meaning in each culture. Gadamer in his writings talked
about the culture most familiar to him—modern Western culture—from the point of view
of an elderly German citizen.
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The author (Gadamer, 2004) provided an important historical overview of
science and of medical practice as a subset of science. He also offered a critique of the
current Western medical practice for its overreliance on natural science research model.
Gadamer stated that the modern medical practice is a scientific practice and as such
“requires knowledge, which means that it is obliged to treat the knowledge available at
the time as complete and certain. The knowledge known from science, however, is not of
this sort” (p. 4). The main assumption of scientific knowledge is that it is never final or
definite. Furthermore, science, Gadamer argued, historically was not sought out for its
practical applicability, “[science] understood itself . . . as pure theoria, that is, as
knowledge sought for its own sake and not for its practical significance” (p. 4).
For Egyptian geometricians and Babylonian astronomers, knowledge
accumulated from practice and was not valued apart from it. In Ancient Greece for the
first time, “science and its application, theory and practice, parted ways” (Gadamer,
2004, p. 5). The “modern relation between theory and practice, which was formed by the
seventeenth-century idea of science” was based on Cartesian “ideal of certainty [that]
became the standard for all understanding” (p. 5). Furthermore, Gadamer stated,
Only that which could be verified could have validity as experience. In
seventeenth century, experience thus ceased to be a source of starting point of
knowledge but became, in the sense of ‘experiment’, a tribunal of verification
before which the validity of mathematically projected laws could be confirmed or
refuted. (p. 5)
In other words, Gadamer suggested here that only experience that was verified by
experiment could serve as a datum for knowledge. Modern science still lives by these
ideals of verifiability and testability. However, Gadamer provided an important
observation—modern natural science is not “knowledge,” but a “know-how.” This,
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Gadamer stated, made knowledge a practice. Know-how is an expertise on how to do
something (“Know-how,” n.d.) rather than an accumulation of information on a subject.
Gadamer (2004) discussed the idea of science as an instrument of technology
and its impact on human development. He particularly warned his readers to pay
attention to the ethics in scientific practice. Gadamer postulated, regarding the significant
pressures that science was facing in modern times,
On the one hand this leads to the emotional blindness with which a mass critique
of culture reacts to these phenomena, and it is necessary to avert in time the
iconoclasm which threatens from this quarter. On the other hand there is the
superstitious faith in science which strengthens the technocratic unscrupulousness
with which technical know-how spreads without restraint. In both respects
science must carry on a kind of demythologization of itself and indeed by its very
own means: critical information and methodical discipline. (p. 7)
Thus, Gadamer disclosed his concern about the rapid progress with which science was
taking over our day-to-day lives. He provided two possibilities: blind following of
scientific progress might lead to unquestioned spread of technology, which could be
destructive to humanity. On the other hand, the society might renounce the scientific
progress altogether, which consequently could be detrimental as well. Science has
brought many important innovations into the modern world. Specifically when it comes
to medicine and healing, modern science inventions provide an unmatched level of care
for traumatic injuries and disabilities. It is unimaginable the way modern medicine can
reattach torn parts of the body, safely deliver babies in the most complicated births, and
bring functional artificial limbs to people, who lost theirs in traumatic accidents or in
wars. Throwing away all of the inventions that science brings to people would not be
humane. However, for Gadamer, it remained important to keep science doing what
science did best—natural phenomena—and not allow it to uncontrollably permeate
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human phenomena. When science does the latter, it reduces the rich and complex human
experience to nuts and bolts of a mechanical machine and takes away its humanity.
Additionally, the philosopher explained his apprehension about modern science’s
inaccessibility. Gadamer (2004) argued that science as it was developing prior to the
twentieth century was still available to the layperson or scientists from other fields via the
“paths of well-organized information” (p. 8), which made it possible to partake in
scientific knowledge. However, starting in the early twentieth century, the “expansion of
research and its increasing specialization have led to a deluge of information which turns
against itself” (p. 8). This made scientific knowledge difficult to organize and store and,
therefore, difficult to access. This difficulty of access makes the scientific information
privileged and scarcely available for examination by the society or other fields for ethical
or political reasons. This inaccessibility of scientific knowledge was risky, Gadamer
implied, as it prohibited public critique, discourse, and accountability.
It is important to note that Gadamer (2004) wrote his collection of essays, The
Enigma of Health, in the time before the internet became as widespread as it is today in
2015. Along with the availability of internet access, scientific publications also became
very accessible. Nowadays, anyone with a smartphone and internet connection can have
almost any published scientific article literally at their fingertips within seconds or
minutes. Some of these publications are free, although access to many may become
prohibitively expensive, at $30 or more per article. However, despite these apparent
improvements in accessibility of scientific data, the difficulties remain in integration of
these data and ability to analyze the data by the public. These difficulties, I agree with
Gadamer, are there because of specialization of subfields. Each subfield of science
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creates different jargon and different understanding of similar or sometimes the same
phenomena. Thus, communication between various fields of study and integration of this
information by public or even by the scientists from other subfields becomes increasingly
problematic and, I agree with Gadamer, eventually impossible. Additionally, in science,
the bias for publishing mostly positive results remains a big problem, leading to
misrepresentation of scientific data in each subfield.
Gadamer (2004) further stated, “our progress of knowledge is subject to law of
increasing specialization and, hence, to increasing obstacles to comprehensiveness”
(p. 10). This directly contradicts the ultimate scientific expectation that all knowledge
eventually will come together in a comprehensive theory of the world and of all living
beings in it. Given Gadamer’s carefully outlined perspective on science and knowledge,
however, his conclusion appears to have merit: we can expect that the more specialized
each subfield of science is, the more difficult it will be to bring all of those fields together
into a comprehensive whole. I argue that such a comprehensive theory, which would be
capable of bringing together all of the knowledge collected by science to date, appears
highly improbable given the fragmentation of knowledge that specialization created.
What further complicated things, Gadamer (2004) argued, was what he called
“the institutionalization of science into a business” (p. 17). He stated, “[science] belongs
to the larger context of economics and social life in the industrial age. Not only is science
a business, but all the work performed in modern life is organized like a business”
(p. 17).
There is the artificial creation of needs, above all by means of modern advertising.
In principle what is at stake is dependence on the means of information. The
consequence of this condition is that both the specialist who acquires new
information and the journalist—that is, the informed informer—become social
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factors in their own right. The journalist is well informed and decides how far
others should be informed. The specialist presents us with an unassailable
judgment. If no one other than the specialist is able to judge the specialist, and if
even misadventures or mistake can be criticized only by specialists—one thinks
of the ‘malpractice’ of doctors or architects—an area thereby has become in a
precise sense autonomous. (p. 18)
Furthermore when it came to health and illness, Gadamer (2004) postulated,
“illness is a social state of affairs. It is also a psychological-moral state of affairs, much
more than a fact that is determinable from within the natural sciences” (p. 20). Therefore,
in Gadamer’s opinion, the therapeutic factors are in the patients’ cooperation and the
doctors’ power of persuasion. These factors are affecting an organism beyond the
chemical influences of a so-called medical intervention. It is possible then to draw the
conclusion that the personal qualities of a doctor and his or her talent are of great
importance to the healing process. On the other hand, application of scientific knowledge
should not be affected by such factors as personality and/or special talent. Scientific
knowledge is expected to depend only on testable and verifiable facts. Peculiarly,
Gadamer chose the following words to describe the modern attitude towards medical
doctors and it is surprisingly similar to the one humans had towards their healers many
centuries ago,
in spite of all the progress which the natural sciences have brought about for our
knowledge of sickness and health, and in spite of the enormous expenditure on
rationalized technology for diagnosis and treatment which has taken place in this
area, the sphere of the unrationalized element within it is particularly high. This
shows itself in the fact that even now, as in the oldest times, the idea of a good
doctor or even of the medical genius has much more of the prized esteem we
think characteristic of an artist than of a man of science. (p. 21)
Modern Western society highly values scientific developments and greatly relies
on the knowledge and the know-how they provide. However, relying so heavily and
blindly on scientific knowledge can be risky. Gadamer’s (2004) main critique of
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scientific know-how is that it is hermeneutically “limited to what it must answer by its
questions. This is a hermeneutic structural element of all research. In itself it is still not
‘practical’ knowledge” (p. 28). In other words, the science will only provide answers to
the questions that the scientists ask. Moreover, the questions that are asked are formed
within the current cultural and temporal horizons thus are not universal in their nature,
but relevant only to today’s reality. Another important hermeneutical limitation is the
fact that “researchers cannot always eliminate value expectations or that they will often
interpret their findings under the impress of inappropriate prejudices—I am reminded
again of the Darwinism in social research” (p. 29).
According to Gadamer (2004), a physician is simply a “man [sic] with a body of
knowledge” (p. 31), thus his or her personal genius and talents will play a role in how he
or she delivers healing. The physician would not just make somebody healthy, Gadamer
stated, “Thus it must always remain an open question just how much the successful
restoration of health owes to the experienced treatment of the physician and how much
nature itself has assisted in the process” (p. 33). Moreover, to Gadamer, health was a
natural state of equilibrium, and thus healing someone from an illness involved
reestablishing the lost equilibrium. He observed that when one attempted to produce an
equilibrium, then one was “thrown back, as it were, by something that is somehow selfsufficient and complete” (p. 37). Therefore, the medical field is not concerned with
establishing an equilibrium of health, but instead works on “arresting and assisting” the
already existing and ever shifting equilibrium (p. 37).
Physicians are facing the task of having to address the whole to achieve
convalescence, because Gadamer’s equilibrium affects the wholeness of the human
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experience. Moreover, Gadamer (2004) stated that the loss of such equilibrium did “not
merely represent a medical-biological state of affairs, but also a life-historical and social
process” (p. 42). To Gadamer, the person who has succumbed to an illness is not the
same person who was there before. The ill individual loses the balance and figuratively
speaking “falls out” of his or her “normal place in life” (p. 42). One of the important
aspects for physicians, when keeping in mind Gadamer’s idea of equilibrium, is to
“neither make patients wholly dependent on them, nor needlessly prescribe dietary or
other conditions of lifestyle which would only hinder patients from returning to their own
equilibrium of life” (p. 43).
There are other dangers of accepting science without question as the only means
to healing. For example, Gadamer (2004) discussed the idea of objectification of bodily
experiences and of the body—the same objectification that science enhanced. Scientific
exploration requires the objectification, the breaking down of the whole into its parts, and
a careful analysis of each separate fragment of the human body. Such objectification,
Gadamer stated, “demands of all of us a violent estrangement from ourselves, irrespective
of whether we are doctors, patients, or simply responsible and concerned citizens”
(p. 70). He found risky this estrangement of humans from their bodies because, in his
opinion, the idea of health was broader and more comparable to an equilibrium that kept
both the internal physical states, emotional states, and external environments in balance.
However, through the methodological procedures that the modern science brings, it
objectifies the experience of living in the world. In his work, Gadamer expressed his fear
of losing the greater whole by breaking it into its parts via reductionism coupled with
objectification.
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Etymologically, Gadamer (2004) noted, the word health had its origins in “the
Greek experience of the world” (p. 73) and reflected the idea of “whole of being” or hole
ousia. Meanwhile, the illness feels like Es fehlt mir etwas or “I am lacking in something”
when translated from German (p. 73). Gadamer further noted that when illness was upon
their bodies, humans noticed a disruption in something (health) that usually, when not
disturbed, escaped human attention. In his opinion, the condition of well-being was the
condition of not noticing. This is the condition of not noticing the body or equilibrium in
which the body resides. Thus, the author asked the question, “what does illness tell the
one who is ill? (p. 76). He then logically proceeded to ask an even more provocative
question—“Can learning to ask such a question of oneself perhaps even contribute to
helping the one who is ill?” (p. 76).
The fundamental fact remains that it is illness and not health which ‘objectifies’
itself, which confronts us as something opposed to us and which forces itself on
us. In fact, we always describe something as a ‘case’ of illness. The German
word for case is Fall. What does Fall mean here? The use of the word
undoubtedly comes from the game of dice. From there it has entered into the
language of grammar and the rules of declension. It refers to the role which
‘falls’ to a noun within a sentence. (The Greek for Fall is ptosis, which in Latin
becomes casus). Similarly, illness is something which ‘befalls’ or ‘falls’ to us,
something we experience as a chance or accident (Zufall). (p. 107)
Gadamer (2004) made another important conclusion from his careful observation
of our modern culture—health was not what was observable to us. Instead, it was illness
that humans were able to observe, measure, analyze, and treat. Therefore, he concluded,
when medical science established standard values for health and imposed those standard
values onto a healthy human being that resulted in making him or her ill. “The appeal to
standard values which are derived by averaging out different empirical data and then
simply applied to particular cases is inappropriate to determining health and cannot be
forced upon it,” he postulated (p. 107). Gadamer further explained the reason for using
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the word inappropriate in this case. Inappropriateness was due to health not being truly
measurable for each separate individual, as it was a “condition of inner accord, of
harmony with oneself that cannot be overridden by other, external forms of control”
(p. 108). Consequently, one of the most important indicators of someone’s illness is their
self-report of not feeling well.
The author illustrated how our use of language highlighted the importance of the
inner experience that could not be measured:
The role of the doctor is to ‘treat’ or ‘handle’ the patient with care in a certain
manner. The German word for treating a patient is behandeln, equivalent to the
Latin palpare. It means, with the hand (palpus), carefully and responsively feeling
the patient’s body so as to detect strains and tensions which can perhaps help to
confirm or correct the patient’s own subjective localization, that is, the patient’s
experience of pain. The function of pain in the living body is to register through
subjective sensation a disturbance in that harmonious balance of bodily processes
which constitute health. (Gadamer, 2004, p. 108)
Similarly, the word handle in English implies the use of hands as well. Gadamer further
believed that the doctors who were able to identify the location of the pain accurately
“are in possession of a true ‘art’” (p. 108). To strengthen his point, Gadamer provided a
couple of examples where a doctor’s skill of identifying an anomaly in the human body
without the use of supplemental devices had been admired and acknowledged as a
superior skill and a true talent.
Additionally, illness does not manifest the same way in everyone. Instead,
Gadamer (2004) observed, human ability to think about themselves contributed to the
experience. For example, psychosomatic conditions illustrate this point quite clearly—
human suffering in one’s environment (e.g., conflicts at a workplace) may translate into
various somatic symptoms.
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The last important factor that Gadamer (2004) identified as contributing to
treatment was human “desire for authority” (p. 120). He wrote, “even in a state of perfect
enlightenment we cannot ground everything we hold to be true through strict proof or
conclusive deduction. Rather, we must permanently rely on something, and ultimately on
someone, in whom we have trust” (p. 121). It was “genuine authority” that humans
sought, he believed. This genuine authority “is recognized as involving superior
knowledge, ability and insight” (p. 121). Hence, the authority of science is so important
and understandable in modern medicine—it fulfils the need so perfectly. In our
“scientific age” the authority of science “is grounded in the superiority of that knowledge
which has been accumulated and passed on by science as an institution” (p. 122). Of
course, the authority of science ultimately relies on humans conducting science.
Gadamer stated,
Now method and methodology are, in fact, the hallmark of science. But they
possess a human background. The self-discipline which allows someone to keep
to a method—against those inclinations, assumptions, prejudices and subjective
interests which tempt all of us into believing to be true only what suits us—here
claim its superior value and validity. It is on this that the true authority of science
rests. . . . In truth, modern science presents an impressive embodiment of critical
freedom that is to be marveled at. But we should also be aware of the human
demand that is placed on all those who personally participate in this authority: the
demand for self-discipline and self-criticism, and this is an ethical demand.
(p. 122)
On Health, Illness, and Treatment
As summarized above, to Gadamer (2004), health was an equilibrium between
one’s self, parts of one’s body, and his or her environment (including one’s relationships
with other people and objects around a person). Thus, illness was an unbalanced state of
events and a lack of equilibrium. Similarly to Gadamer, Eisenberg (1977) almost four
decades earlier also noticed that doctors deal with diseases; however, the illnesses
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included social aspects of diseases as well. Thus, when doctors focus on treating organs
and dysfunction in organs, patients also experience the impact of disease on their states of
being and social functioning (i.e., loss of equilibrium described by Gadamer).
When illness comes and the equilibrium is lost, several if not all of the person’s
aspects of being are affected. For instance, if someone has a common cold, they feel
discomfort in various parts of their body. They often choose to stay inside as it becomes
difficult or impossible to complete the simplest tasks. They are not able to talk and
engage with others at the same level they could prior to the onset of their symptoms.
These behaviors in turn trigger changes in the environment and the person’s relationships
with the world are affected. All become difficult to do: performing their jobs, carrying
for their children, sustaining relationships with colleagues/peers and loved ones. The
person now feels ill not only because of the physical challenges (e.g., achiness and fever),
but also because many of the meaningful things in the environment qualitatively have
changed.
Therefore, in accordance with Gadamer’s (2004) conclusions, treatment is the
restoration of the lost equilibrium via various approaches. Thus, treatment should and
often does address the bigger picture, not only the common cold symptoms, or a broken
foot, for instance. The treatment process is meaningful as we associate this process with
the restoration of the lost equilibrium.
Television commercials for cold and flu remedies are a good illustration of this
loss of equilibrium and of the following restoration of it by means of the advertised
treatments. When people in the commercial video succumb to the common cold
symptoms, they behave as if in a fog, unable to interact with their environment. They
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appear disconnected from the world around them and look miserable. They are then
displayed taking the advertised remedy and it provides them with the ability to talk to the
coworkers again, give presentations, care for their children, etc. Visibly, the equilibrium
has been restored.
Such advertisements are the products of our culture. They are historical artifacts
as hermeneutists would say. By the virtue of being a cultural artifact, an advertisement is
situated within a culture and it embodies and reflects the culture. In other words, it is
meaningful to the representatives of a culture, which produced this artifact.
These commercials illustrate how the advertisers appeal to the meaning of
treatment. Treatment is not just a relief from the cold symptoms. Most importantly,
treatment is a reconnection with the rest of the world and feeling like oneself again.
These commercials appeal to the audiences and help to sell the products because they
address that which the individuals with the cold symptoms are actually seeking—
restoration of equilibrium in their meaning-laden lives. The meaning of treatment, in the
end, is not primarily concerned with physical well-being, but to a great extent with what
the physical well-being represents.
There is another important aspect of treatment—treatment should be restoring the
equilibrium and not creating a different one. Just as in the cold medicine commercial,
people expect the treatment to happen without much disruption to their usual ways of
being. Activities such as quickly popping a pill for a few days or drinking a tablespoon
of syrup at night only minimally disrupt the person’s usual way of life. Then the
equilibrium is restored via reducing the flu symptoms and making one’s body feel less
achy or feverish. Another way of restoring the equilibrium, for instance, could be to ask
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people to power through their symptoms and not miss family gatherings or important
office presentations. Alternatively, one could be asked to change their environments in a
way that would allow the sickness to continue while not interrupting other aspects of life.
If one does not have a job to go to, then why not just stay in bed all day?
These latter options of achieving the equilibrium seem less appealing because
they propose to reset the equilibrium itself, not to restore the previously existing one. It
is the restoration of the previously existing equilibrium that people seek when they seek
treatment, according to Gadamer (2004). In line with his postulates, people wish for a
treatment process that would not cause significant change to their routine. The goal is to
restore the equilibrium, but not to create a different one.
Additionally, people seek treatments which they are already used to and tend to
associate with positive results. This idea of familiar treatments associated with positive
results resembles the elements of the concept of classical conditioning. Thus, both the
idea of restoring the equilibrium and the idea of classical conditioning, referenced by
Benedetti (2013), appear to refer to similar processes. People seek healing methods that
are meaningful to them and classical conditioning phenomenon may be contributing to
creating that meaning. Through the process of classical conditioning, one builds an
expectation of what is to come. Sometimes that expectation is covert, but often it is overt
and, therefore, the connection between the stimulus and the response becomes
meaningful for people. Thus, when certain treatments are associated with certain results,
people learn to make a more conscious connection of positively associating the healing
procedures with the positive results (e.g., with feeling better).
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Furthermore, meaningfulness of a treatment is bound to a particular culture. In
the United States, treatment options that involve taking tablets, capsules, pills, or syrups
are some of the most popular. The healing ritual of taking a pill is very meaningful in
mainstream U.S. culture. Most diseases, disorders, maladies, or ailments have at least
one drug developed to treat them or symptoms associated with them. Representatives of
the mainstream U.S. culture may find nothing unusual or noteworthy about the fact that
they take pills so commonly to treat various ailments. However, not in every culture do
healing rituals favor pill taking. For example in Russia (also a country with
predominantly Western views), many people find a series of painful intramuscular
injections to be a superior treatment for a severe cold or other ailment. They find
injections to be a meaningful and powerful form of treatment. Injections are often
considered more potent than pills in Russia. The treatment preferences of Americans and
Russians that I described here are personal observations from the point of view of a
bicultural person. To my knowledge, there are no studies that show the prevalence of
injectable treatments in Russia. In my experience, injectable treatments are
commonplace in Russia as a home treatment, whereas I rarely hear of such treatments
outside of clinics and hospitals in the United States. This observation, of course, is
debatable in absence of specific data. I provided this observation of the difference in
treatment options to illustrate that even in Westernized societies mainstream treatments
may vary due to cultural differences.
Bhugra and Ventriglio (2015) also acknowledged that culture influences how one
perceives his or her distress or healing. Other research in the past showed that cultures
sometimes attached opposite meanings to healing methods. Buckalew and Coffield
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(1982) discovered that Caucasians were more likely to see white capsules as analgesics
and black capsules as stimulants. However, African Americans in the same study saw
black capsules as analgesics and white ones as stimulants. These variations appear to
result from the differences in aspects that make up a culture at any particular historical
point in time and location.
Natural Sciences Versus Human Sciences
In modern Western society, there is an accepted distinction between natural and
human sciences that Gadamer (2011) alluded to in his writings. Human sciences are
fields of study that explore the nature of humans, human relationships, aspects of human
psyche, and individual and public relationships within human societies. Examples of
human sciences are sociology, psychology, and anthropology. Natural sciences, on the
other hand, deal with the matters of the material world in which humans exist. Natural
sciences include fields like mathematics, physics, chemistry, biology, geology,
hydrology, and dozens of other fields and subfields. Additionally, medicine and
engineering are treated as scientific subfields and fall into the category of applied
sciences (Ossenbrink & Stephan, 2013). They deal with specific practical applications of
natural sciences like physics, chemistry, or biology for solving various issues that humans
face.
Sciences have originated and triumphed in Western culture. In this culture,
humans clearly label and distinguish the differences between the fields and subfields of
sciences. Moreover, there are some differences between human and natural sciences that
appear categorically significant and important. Specifically, there is a general sense in
Western culture that human sciences are inferior to natural sciences. Even though in
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Ancient Greece, all arts and sciences were equally important and worthy of pursuit, but
this changed in the time of Descartes. Gadamer wrote about this shift in The Enigma of
Health (2004). Also, Clarke (1982) wrote that Descartes had
a pivotal role in the history of this development, in the transition from a widely
accepted scholastic concept of science to its complete rejection by practicing
scientists and the endorsement of some kind of hypothetical, empirically based
knowledge of nature. (pp. 258–259)
Since Descartes, a more positivistic approach has been cultivated in science in which
experience is valid only if observable and measurable (Carnap, 1936). Certainty is now
of most importance. Gadamer (2004) wrote that the truth had been reduced to certainty
(p. 148). However, certainty is difficult if not impossible to achieve. Some experiences
studied by human sciences are not easily observable or measurable. This makes human
sciences less objectifiable, less quantifiable, and consequently presumed to be inferior to
natural sciences, where subjects by their nature are more likely to be objectively
measured and quantified.
In scientific discourse as well as in general public, the bias exists in favor of
natural sciences. In addition, there exists a prejudice against things not quantifiable or
measurable. Gadamer (2011) stated, that even when human sciences were acknowledged
for producing a different kind of knowledge, one might still “describe the human sciences
in a merely negative way as the ‘inexact sciences’” (p. 5). It appears as though Western
culture produced not only science and scientific inquiry, but also a cult of science and of
such scientific inquiry based on natural sciences methodology. I use the word cult here to
describe a system of religious-like worship and ritual (“Cult,” n.d.). Usually, scientific
inquiry is viewed as a way to understand and describe the world in which humans live.
However, the difference between a way something is done and a cult is in the amount of
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open questioning of the process. In a cult, the authority of the idol is not questioned.
Similarly, Western culture rarely questions the goodness of rigid, objective scientific
inquiry. There is a strong assumption, that scientific inquiry is always good and the more
precision the better.
This idea of blind following of scientific ideals has already been described and
critiqued. Psychotherapist and author Phil Cushman (1995) warned modern
psychologists and other professionals of the risks they took when they did not question
science. One of the most commonly used terms is the word scientism or its adjective
form, scientistic. They describe the invasion of science into every aspect of human
functioning with an exaggerated belief in the principles and methods of science
(“Scientistic,” n.d.). Scientism is defined as “the belief that the assumptions, methods of
research, etc., of the physical and biological sciences are equally appropriate and
essential to all other disciplines, including humanities and the social sciences”
(“Scientism,” n.d.).
The assumption that science is always good is not always accurate. Let us review
the process of scientific inquiry in human sciences for example. When it comes to
describing and measuring human phenomena, few things are easily identifiable and
measurable. In natural sciences, researchers name, describe, and then measure various
aspects of nature (e.g., rocks, chemical elements, electrical and magnetic forces, etc.). In
human sciences, on the other hand, there are no analogous clearly identified objects of
study. Hence, scientists develop constructs for which they can later develop measuring
procedures. For instance, such aspects of human experience as mind or emotion cannot
be easily isolated and measured. First, the construct has to be created—a word to
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describe the experience. Not every human culture has words to describe these
concepts—mind and emotion. When they do, the concepts would not necessarily
represent the same aspects as mind and emotion do for English speakers. Thus,
linguistics largely determines what is studied by the human sciences.
Social constructionists argue that human language determines human experience
in general and this is not only true of human sciences (Gergen, 2009). An important fact
to acknowledge is that any distinctions that humans identify between natural and human
sciences are abstract and constructed by humans as a form of cultural artifact. Science
accepts these constructs as hypothetical. However, mainstream Western culture as well
as individual scientists often forget that these constructs are artificial and hypothetical
and instead accept them as objective experiences. These constructs are meaningful in the
particular way only in the given time, place, and culture. These ideas of constructed
reality are described in more detail in the writings by social constructionists like Gergen
(2009) and hermeneutists like Gadamer (2011) and Cushman (1995).
In Gadamer’s Truth and Method (2011), he addressed a number of points now
relevant to this study. He made a strong argument for medicine being a human science
rather than a natural science. In Western society, medicine is an applied science and
generally follows the natural science model. Thus, it is under the influence of the cult of
science and scientific inquiry, in other words, of scientism. This metaphorical cult of
science dictates that all information gathering should ascribe to the logic of natural
science. Cushman (1995) stated, “the modern Western society . . . slowly developed an
intense belief in rationality and the scientific practices of quantification and
objectification” (p. 21). Cushman and Gadamer appear to agree that quantitative methods
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of inquiry are favored in the modern Western world. Indeed, anyone can experience this
favoritism by simply looking at the research section at a local library or by doing a simple
internet search. One is likely to notice that the majority of textbooks and scientific
publications include an abundance of quantitative data and complex statistical analyses to
investigate and draw conclusions from those data.
For instance, in the fields of clinical and counseling psychology, research plays a
fundamental role in establishing understanding of psychological phenomena and best
clinical practices. An example of a popular research methods textbook that graduate
students in psychology use is Research Design in Counseling by Heppner, Wampold, and
Kivlighan (2008). This textbook consists of 22 chapters. Out of these, 19 have
information pertaining to research methods and clarifications around such methods. The
headings of these chapters do not specify what type of research methods they are.
Instead, they use generic names such as: “Science and counseling,” “Research training,”
“Choosing research designs,” and “Major research designs.” In Part 2 of the textbook,
which is labeled “Major research designs,” there are five chapters. Four of them discuss
quantitative research designs without overtly specifying that they are quantitative.
However, one chapter stands out—it is named “Qualitative research.” It is of note that
qualitative research methods—the research methods developed specifically for studying
phenomena in human sciences—take only one fifth of the section on research designs in
the textbook developed for human science graduate programs. Additionally, only this
chapter in the textbook contains a subsection called “Myths and facts about qualitative
research” (p. 259), which in many words outlines common misunderstandings about
qualitative research. The misunderstandings outlined by the authors show the common

57
thread—qualitative research is less trusted and is not considered scientific enough. It is
also the type of research that is usually labeled with a specifier “qualitative” in literature
and textbooks. Quantitative research methods are rarely clarified with a label
“quantitative,” as simply writing “research” is usually enough.
The example of the Research Design in Counseling textbook (Heppner et al.,
2008) is only one in many and suggests that the field favors quantitative over qualitative
methods and often requires that qualitative methods defend themselves and prove that
they too provide valid research by having sections such as the “Myths and facts about
qualitative research” in textbooks, dissertations, or scientific articles. The implicit
message here is that all knowledge gathered in other ways or that is not measurable by
quantitative methods is not valid or is of less value than knowledge gathered using
positivistic scientific methods.
Gadamer (2011) stated, “the logical self-reflection that accompanied the
development of the human sciences in the nineteenth century is wholly governed by the
model of the natural sciences” (p. 3). However, human sciences, he argued, had their
own logic. In the culture where natural sciences and natural-science ways prevail,
however, it is difficult for human sciences to stay credible unless they succumb to the
natural sciences logic.
Human science too is concerned with establishing similarities, regularities, and
conformities to law which would make it possible to predict individual
phenomena and processes. In the field of natural phenomena this goal cannot
always be reached everywhere to the same extent, but the reason for this variation
is only that sufficient data which the similarities are to be established cannot
always be obtained. Thus method of meteorology is just the same as that of
physics, but its data is incomplete and therefore its predictions are more uncertain.
(Gadamer, 2011, pp. 3–4)
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In human sciences, it appears that it is not the lack of data that creates uncertainty.
Instead, the uncertainty seems to be there because it is a different dynamic system
altogether. Where humans, human psyches, and behaviors are involved, there exists a
great deal of uncertainty and unpredictability. Psychological theories are at best
operating on low percentages of probability when predicting individual human behavior.
This occurs for the simple reason that scientists cannot ever create a laboratory condition
where an individual human behavior can be predicted. Humans live, breathe, and, most
importantly, think at all times. It is now evident, even using limited scientific data, that
humans’ context creates their reality. For instance, body language of a person is a
powerful communicator and has been found to not only send signals outward to the
community, but also inwardly in terms of changing the person’s own neurochemistry
within a short time of just two minutes (Carney, Cuddy, & Yap, 2010). When a person’s
hormonal and neurochemical balance is changed, that person reacts and behaves
differently. Modern imaging techniques are now capable of showing that the neural
pathways of the brain change constantly under the influence of drugs, medications,
meditation, and even conversations (i.e., psychotherapy) (Cozolino, 2010).
Human culture and social behavior consist of many individual behaviors,
thoughts, and choices. This makes the system of social interaction and individual human
behavior too complex and dynamic to be able to make clear predictions. Many human
actions appear to be based on people’s belief systems and cultural backgrounds as well as
individual circumstances in the moment. Moreover, even when the current scientific
understanding of human behavior is applied (i.e., things that appear observable and
measurable such as changes in human biochemical makeup and brain activity), scientists
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run into problems in being able to understand and predict human phenomena. This is
because biochemical makeup and neural pathways in the brain and even human genes
change due to not only biochemical or physical interventions but also to various
contextual phenomena.
When scientists think of observable and measurable changes in physiology as a
way to prove that some change in a human has occurred, they connect the observable
changes to a physical or biochemical intervention that they performed. Since they do not
have a way of observing, measuring, or testing a constantly changing cultural, historical,
temporal, and other contextual environment, they tend not to connect the observable
changes in humans to context as readily as they do with other interventions. Therefore,
even when observable changes happen and are carefully measured (such as in imaging
studies of placebo response), scientists are hesitant to attribute these changes to
contextual factors. Benedetti (2013) warned scientists and public that even though
placebo response produced measurable changes, this did not put the placebo response on
the same level of efficacy as drug interventions. Moreover, efficacy of study drugs in the
psychopharmaceutical studies is argued to be representative of their effectiveness in real
world, so the drugs may be sold on the market. However, the same logic is not applied to
placebos, and their efficacy in the clinical studies is not argued to suggest a possibility
that they could be effective as a treatment in real world.
Summary of Benedetti’s 2013 Review
This article, “Placebo and the New Physiology of the Doctor-Patient
Relationship” (Benedetti, 2013), is one of the most complete summaries of the placebo
response as it is understood by modern medicine and psychology. I provided highlights
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of this article here as an attempt to give the most recent overview of the current state of
research on placebo. I chose to rely on Dr. Benedetti’s work as one of the most
prominent experts in the field of placebo research. In this recent work, Benedetti
provided a thorough synopsis of placebo research and the new understanding of placebo
response as a contextual phenomenon. Benedetti (2013) wrote that the context was
mediated to the large extent by the relationship with the doctor. He began his 2013
overview by identifying the term placebo and its history. Specifically, he stated that back
in the 18th century placebo was first used as a comparator to identify whether mesmerism
was indeed an efficacious treatment modality. This was the first time that a sham
treatment successfully demonstrated that mesmerism was not what it claimed to be.
Eventually, the word sham was replaced with the word placebo. Since that first official
use of a sham procedure, placebo entered the world of clinical investigation as a
comparator treatment for efficacy evaluation of various treatment modalities.
Benedetti (2013) next provided a summary of how placebo was used in modern
science to help researchers understand the way the human brain works. The researchers
used the terms placebo effect and placebo response very much interchangeably. The
author identified that various aspects were influencing placebo response “such as the
relationship between the doctor and his patient, the patient’s expectations and needs, the
patient’s personality and psychological state, the severity and discomfort of the
symptoms, the type of verbal instructions, the preparation characteristics, and the
environment milieu” (p. 1208). Additionally, he stated that “the merits of
conceptualization of the placebo effect as a mind-body phenomenon reside in the fact that
it makes us understand that the placebo effect is due to the psychosocial context around
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the patient and the therapy” (p. 1208). Moreover, he underlined that “when a treatment is
given to a patient, be it sham or real, it is not administered in a vacuum, but in a complex
set of psychological states that vary from patient to patient and from situation to
situation” (p. 1208). Thus, Benedetti identified the following contextual pieces that
influenced placebo response: “words by doctors and medical personnel,” “sight of health
professionals, hospitals, and medical instruments,” “interactions with other patients and
people,” “touched by needles and other devices,” “color, shape, smell and taste of
medications” (p. 1209). It appeared that the author recognized that symbolisms and
rituals mediate placebo response.
Benedetti (2013) further discussed other changes that may be confused with
placebo response, such as regression to the mean, natural history of the disease,
unidentified co-interventions, and biases of patients and healers. Overall, the author
provided the following breakdown of what placebo response was made of when used as a
comparator to active treatment: natural history (i.e., spontaneous remission), regression to
the mean, co-interventions, experimenter’s and patient’s biases, and psychobiological
factors (p. 1210). The combination of all or some of the above leads to clinical
improvement when placebo is administered. The author acknowledged that because
these variables constituting placebo response were not controlled for in clinical trials,
clinical trials were not a good way for understanding placebo response.
Next, Benedetti (2013) discussed the effect of the doctor-patient relationship on
placebo response. He made an argument for the evolutionary nature of grooming
behaviors, where both the groomer and the groomed (i.e., the healer and the patient) were
genetically predisposed to feel the benefits of the process and changed in response to the
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grooming. The biological changes identified via MRI studies showed the patient’s
response in expectations, trust, and hope when the patient met his or her doctor. The
doctor’s brain also showed changes that involved activation of empathy and compassion.
Additionally, the author discussed auditory/language systems that affected one’s placebo
response. Specifically, using reassuring language, as his earlier research had shown,
produced considerably stronger placebo response (Benedetti, 2002). Humans
additionally took into consideration the facial expression of their healers (e.g., medical
personnel), eye contact, gestures, and touch, with all influencing improvement. Benedetti
stressed that trust and hope were activated in response to the above factors and “these, in
turn, lead to expectations and beliefs, which represent some of the principal elements
involved in placebo response” (p. 1216). Benedetti explained the participation of various
brain areas in those processes and particularly underscored the involvement of amygdala
in trust assessment.
Benedetti reviewed an additional aspect of placebo response as a meaning
response in the 2013 article. Specifically, he provided an example of a postoperative pain
experience as compared to a cancer pain experience. People reported that cancer pain
was more unpleasant than postoperative pain. The researchers identified the reason for
the difference in experience as the difference in attribution of meaning: cancer pain
meant death and postoperative pain meant healing (p. 1218). He admitted, however, that
the researchers still did not know what mechanisms of placebo response took place and
under what conditions.
It appeared from the research, Benedetti (2013) concluded, that placebo response
involved classical conditioning and expectation as some of the primary driving factors.
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However, the author did not explain how those were involved in nocebo response and in
situations where no previous conditioning occurred. There is some evidence that certain
personalities are more susceptible to placebo response. However, the author did not
discuss why sometimes the same person might respond or not respond to placebo, making
the scientific identification of placebo response mediators very difficult.
Benedetti (2013) additionally discussed the idea of nocebo effect or worsening of
one’s condition based on the expectations derived from the meaning. For example, the
author stated that “negative diagnoses may lead to amplification of pain intensity” as well
as to “unwanted side effects” or to reduced “efficacy of some treatments” (p. 1226).
Interestingly, even the known efficacious treatments or known powerful drug effects lost
their potency when the expectation of receiving those treatments or drugs was removed
or reduced. Specifically, Benedetti provided examples of pain not subsiding as expected
when morphine was administered if the patient was not aware of the drug administration
(p. 1235). Similarly, the cocaine addicts had an increase in glucose metabolism in
response to methylphenidate smaller by almost 50% when they were told that it was not
the drug, but placebo (p. 1233).
Benedetti (2013) acknowledged the placebo response being “activated by social
stimuli and therapeutic rituals on one hand and by drugs on the other” (p. 1236). He also
underlined the important observation that all of the drugs introduced to patients worked
because there were already neural receptors in place that could be activated (p. 1236).
This means that the human body already has the neuronal pathways that are activated
internally using the self-produced neurotransmitters within the chemically closed system
in the absence of externally introduced chemicals.
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Moreover, Benedetti (2013) stated, “drugs are not injected into a vacuum but into
a complex living organism that has expectations and beliefs” (p. 1236). It is not known
to science “whether therapeutic rituals can indeed modify a receptor, so as to change the
drug-receptor binding properties,” but the author also noted that this “seems unlikely as
far as we know today” (p. 1236). He then continued to explain that, according to current
research, even though drugs and rituals might “use the same type of receptors,” the
“receptorial pathways are independent from each other, being located in different areas of
the brain” (p. 1236). Furthermore, placebo response might be heavily dependent on
prefrontal cortex functioning, as Benedetti’s own study showed reduction in placebo
response in patients with Alzheimer’s disease (Benedetti et al., 2006).
Further, Benedetti (2013) described how placebo response might be manipulated
in the lab and that both placebo responders and placebo nonresponders could be created
in a lab setting (p. 1237). For example, placebo analgesia was more robust after first
preconditioning with a real analgesic agent (p. 1237). It appeared that “placebo
responses were found to be affected by learning” and, more interestingly, they were also
comparably affected by social learning (p. 1237).
In conclusion, Benedetti’s (2013) summary article provided the most
comprehensive and most up-to-date scientific overview of placebo response
phenomenon, touching on its history, implementation, and the current theories of
placebo’s mechanism of action. He additionally mentioned the ethical considerations for
using placebo and creating placebo responders and nonresponders in both medicine and
pharmacological research. Benedetti appeared to view placebo as an interesting
phenomenon that was useful for medical research and neuroscience, but which use in
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healing was ethically questionable. He specifically warned of the dangers of “bizarre”
therapies that some could justify as techniques that induced placebo effect.
Nonetheless, Benedetti (2013) acknowledged the significance of placebo effect as
a response to the bedside manner and additionally expressed the hope that this knowledge
could be used by health professionals to “boost” their “empathic, humane, and
compassionate behavior further” (p. 1238). Furthermore, he also stated, “understanding
the physiological underpinnings of the doctor-patient relationship will lead to better
medical practice and clinical profession, as well as to better social/communication skills
and health policy” (p. 1238). At the end of the article, Benedetti made an important
observation that by connecting placebo response to the tangible and observable
neurological and physiological changes, science also risked sending the wrong message
that placebo was somehow equivalent to other traditional medicines (i.e.,
pharmacological treatments). He suspected that such a conclusion could be made by the
general public and the media, and that therefore the scientific community should insure
proper communication between science, ethics, and the media.
Benedetti (2013) identified the following seven factors that might be contributing
to clinical improvement in the presence of placebo or sham treatment: “expectationmodulated anxiety, expectation of reward, learning-reinforced expectations, social
learning, Pavlovian conditioning, personality traits, genetics” (p. 1220). I conclude that if
these factors indeed play a role in a person’s clinical improvement while in the presence
of placebo, these same factors must also be contributing to a person’s improvement in the
presence of a proven medical treatment. Thus, Benedetti’s strong opposition to the use of
placebo as a form of treatment is almost surprising. In his writings, he defended the use
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of drugs, because their efficacy was evident through measurable biochemical changes.
On the other hand, placebo response was equally measurable, yet placebo efficacy was
questioned as a potential form of treatment. Such contradictory opinion is
understandable, if one is working within a narrower scientistic worldview. Scientistic
approach does not question the validity of natural science methodology. Moreover, it
questions the validity of experience that is not confirmed directly by empirical research.
Gadamer (2004) also pointed out this questioning of validity of experience. Since there
is no strong generally accepted scientific hypothesis that explains how exactly placebos
work in an organism, the experience is dismissed as unscientific and of questionable
value.
Gadamer Versus Benedetti on Healing
In this section, I provide a comparison between Gadamer’s and Benedetti’s
assumptions about healing. It is difficult to compare the philosopher’s and the scientist’s
views on placebo response directly. Gadamer never discussed placebo at length in his
writings. Correspondingly, Benedetti did not focus his work directly on the process of
healing. Therefore, I compared the assumptions that both made about the processes of
health, illness, and healing/treatment and drew my conclusions based on this comparison.
As stated earlier in my work, Benedetti’s views are to represent mainstream Western
medicine views.
As seen in Table 1, there were differences in the way Gadamer and Benedetti
viewed health and medical treatment, and similarities in the way they viewed illness. To
Gadamer, health was the state of equilibrium between body, mind, and environment of a
person. To Gadamer the experience of health went unnoticed. It was the experience of
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illness that would make humans notice that something was “off.” To Benedetti, health
was simply a lack of disease. The disease in Western medicine is typically identified via
a set of measurements by medical doctors such as blood tests or X-rays to identify any
abnormality as compared to standard (aka normal) set of values.
Illness to Gadamer (2004) was a loss of equilibrium: a sense of being off balance
between the body, mind, and/or environment—a subjective experience. Moreover,
Gadamer also stated that illness was a social and psychological moral state of affairs
(p. 20). On the other hand, illness to Benedetti (2013) was similarly a state of feeling
sick (subjective experience), where both the physical sensations of discomfort and
psychological interpretation of the sensations were at play. However, Benedetti never put
significance on the role of society in illness.
Medical treatment or, in other words, healing was viewed differently by Gadamer
and Benedetti. Gadamer (2004) believed that treatment included meaningful rituals and a
process of meaning-making. Benedetti (2013) wrote that medical treatment context
included rituals such as sight of medical environment and personnel, words spoken by
doctors, touch, taste and smell of medications, and interactions with other people.
Benedetti stressed in his writings that the context described above was influencing
treatment, but never constituted treatment. Moreover, he stated that “the very act of
administering a treatment is a psychological and social event that is sometimes capable of
inhibiting a symptom such as pain, even though the treatment is fake” (Benedetti, 2013,
p. 1213). Therefore, I concluded that a real treatment to Benedetti was only an active
treatment. Placebo would never constitute a true treatment to Benedetti. However, based
on Gadamer’s assumptions about treatment, placebo could constitute a true treatment.
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There were both similarities and some differences in the way the two men saw
aspects of healing/treatment. Trust was something that both Gadamer and Benedetti
agreed was a necessary part of healing. Gadamer (2004) called this aspect “authority”
and described a need humans had to have someone they could trust. They needed
someone who would have “superior knowledge, ability and insight” because alone one
human was not capable of having the necessary knowledge and ability to heal (p. 121).
Unlike Gadamer, Benedetti (2013) viewed trust as an evolutionary adaptation of species
to live as a social group and help each other.
Context was an important part of healing to both Gadamer and Benedetti.
However, Gadamer (2004) considered culture or cultural-historical context as the primary
setting in which healing occurred and from which healing was, essentially, made. To
Benedetti (2013), psychosocial context, personal expectations, and Pavlovian
conditioning constituted context that influenced therapy.
Both authors believed that beliefs and expectations influenced healing. The
beliefs and expectations that Gadamer referred to were part of culture-specific beliefs and
expectations. To Benedetti, those were personal beliefs, expectations, and memories of
previous treatment experiences. Benedetti did not place a significant role on cultural
context and social consciousness, but instead focused on cognitions of a specific
individual.
Doctor-patient relationship was another important aspect of healing that both
Gadamer and Benedetti identified. Gadamer (2004) viewed doctor-patient relationship as
a place where the important meaning-making that constituted healing took place.
Authority, words, concepts, and care that doctors shared with their patients provided
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healing. Benedetti, on the other hand, believed that experimenter’s (a form of doctor)
and patient’s biases contributed to clinical improvement following placebo
administration. He also stated that doctors’ words of reassurance and the trust patients
placed in doctors contributed to healing outcomes. Nonetheless, Benedetti’s (2013)
words (i.e., “biases”) suggested that he believed improvement associated with doctorpatient relationship to be important and yet not the main aspect of healing. There was
negative connotation in the words he chose to describe improvement following placebo
administration, which suggested his own bias against placebo as a true treatment.
In conclusion, there were many similarities in Gadamer’s and Benedetti’s views
about healing. Specifically, they both considered context an important part contributing
to improvement. However, one of the most important differences between their
assumptions was the value they placed on cultural-historical context. To Gadamer, such
context constituted the place where and through which healing occurred. To Benedetti,
social-cultural or historical aspects were of no significance as he placed value only on
individual beliefs, attitudes, and previous experiences.
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Table 1
Differences and Similarities Between Gadamer’s and Benedetti’s Assumptions
Health, Illness, and Treatment
Health

Illness

Medical treatment

Gadamer
Unobservable state of equilibrium
in the absence of illness, a balance
between environment, body, and
mind (Gadamer, 2004)
Loss of the equilibrium, some sort
of unbalance in body, mind, and/or
environment. It is also a social and
psychological moral state of affairs
(Gadamer, 2004)
Includes meaningful rituals
conducted by doctors and/or
caregivers who are trusted as
authority that can restore the
equilibrium. Treatment is culturespecific. It includes culturalhistorical beliefs about health,
illness, and healing rituals and
utilizes words, sight, touch, smell,
beliefs, expectations, interactions
with other people, being subjected
to procedures, etc. (Gadamer, 2004)

Benedetti
Lack of disease
Illness (feeling sick)—bottom-up
processing (detection of sensory
stimuli), top-down modulation
(psychological influences) and
seeking relief (motivation to
suppress discomfort, reward
mechanisms) (Benedetti, 2013,
p. 1213)
Medical treatment is administration
of active treatment
Medical treatment context includes:
Sight, words, touch, smell of
medications, medical personnel,
and clinical environment
(Benedetti, 2009)
Personal beliefs & expectations,
memories about previous
treatments, interactions with other
people, in addition to sight, words,
touch, smell (Benedetti, 2013)

Aspects of healing/treatment

Authority/Trust

Context

Beliefs and expectations

Doctor-patient relationship

Authority is an important aspect of
healing/treatment. One needs to
subject him/herself to authority of
“superior knowledge, ability and
insight” (Gadamer, 2004, p. 121)
Culture is an important context for
meaning-making and therefore for
healing (Gadamer, 2004)
Healing rituals and beliefs are
culture-specific (Gadamer, 2004)

Meaning-making essential for
healing occurs between doctor and
patient (Gadamer, 2004)

Trust is an important aspect of
placebo effect (Benedetti, 2009,
p. 52)
Psychosocial context of medical
treatment plus expectations and/or
conditioning are important parts of
therapy (Benedetti, 2009)
Personal beliefs and expectations,
memories about previous treatment
(Benedetti, 2013, p. 1209) along
with social learning (p. 1220) are
important aspects of placebo effect
Experimenter’s and patient’s biases
contribute to clinical improvement
following placebo administration
(Benedetti, 2013, p. 1210)
“The very act of administering a
treatment is a psychological and
social event that is sometimes
capable of inhibiting a symptom
such as pain, even though the
treatment is fake” (Benedetti, 2013,
p. 1213)
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Placebo Phenomenon as a Human Science Subject
Both human sciences and natural sciences are interested in studying placebo
response and/or utilizing it in some fashion. Benedetti (2009) referred to psychologists
and clinical researchers (who are usually medical doctors such as psychiatrists) both
playing a role in advancing placebo research. However, they appear to define placebo
somewhat differently, albeit still inconsistently, with the former group understanding
placebo response as a psychological phenomenon and the latter group thinking of placebo
response as a composite of various factors such as regression to the mean, classical
conditioning, spontaneous response, etc. More about this difference in definition is
discussed in the final chapter of this dissertation.
Placebo response in psychopharmacological research is a comparator to a
medication effect. Thus, it falls in the same category of phenomena as the natural
sciences-based applied science of medicine. For the clinical research community in the
setting of medical research, placebo phenomenon is implied to be of natural science and
thus is treated as a natural science occurrence. As I argued earlier in the section On
Health, Illness and Treatment, medicine as a scientific field fits better in the human
science category than in natural science, because so much of its healing depends on the
relationship between the doctor and the patient. Therefore, I conclude that placebo
response should also be treated as a human science occurrence.
Summary
In this chapter, I discussed the ideas of health and illness as presented by
Gadamer in his book The Enigma of Health (2004). I illustrated that health, illness, and
healing were an important topic of public discourse in modern Western culture. I further
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provided a summary of Gadamer’s essays discussing the nuances of health, illness, and
healing from hermeneutic point of view. Gadamer offered his view on health as the state
of equilibrium of mind, body, and environment of a human. He compared it to a sense of
balance, a sense of not being disturbed, and a state of “not noticing.” He equaled a state
of illness to loss of such equilibrium—a state when humans would notice that something
was off-balance, or something was bothering them. Further, he concluded, a healing
process would be a meaningful set of rituals enlisted to restore the lost equilibrium. From
a hermeneutic point of view, restoration of the equilibrium would consist of rituals that
were meaningful in a specific cultural-historical space and were delivered by some form
of authority. Gadamer pointed out that authority was an important aspect of healing.
Thus, healers had been individuals who received great respect from their communities at
all times.
Gadamer (2004) stated that natural science model prevailed in conceptualizing
health, illness, and healing, and he provided the historical reasons for this. Conventional
Western medicine, backed by scientific research methods, provided both the meaningful
rituals of healing (i.e., pill taking, exams at doctors’ offices) as well as the necessary
authority—science. Gadamer outlined his critique of overreliance on science when it
came to healing as it brought dehumanization and objectification to the process. He
demonstrated the importance of humanness in illness and healing experiences and
stressed the fact that science did not make someone a good doctor, but certain talent and
personal genius did. He believed that conventional medicine based on natural science
model could do great things for treating physical injuries, but by itself was less equipped
to deal with healing as the restoration of the equilibrium. He pointed out that medicine
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should not be conceptualized as a natural science, but instead should be treated as human
science. I further explored the idea of human sciences and contrasted it with the natural
science model that had prevailed in medicine.
Further, I provided a summary of placebo response understanding and its use in
healing as viewed by Benedetti (2013), one of the leading experts on placebo research in
modern Western science. Benedetti, acknowledged the inconsistency of placebo
response definition in scientific literature and clinical research. He stated that placebo
response and placebo effect had been used interchangeably in research. Additionally, for
the purposes of clinical research, scientists identified placebo response as consisting of
five contextual elements—words of doctors and staff, sight of medical staff and
instruments, interacting with staff and other patients, being touched by medical devices
and needles, and medicaments’ color, shape, smell, and taste. He made a strong case for
importance of doctor-patient relationship in healing. Benedetti also stressed the
significance of meaning that patients gave to their experiences that would shape their
experience of healing. He acknowledged that many contextual and personal meaning
aspects shaped placebo response in patients. I observed that the meaningful contextual
pieces that Benedetti identified seemed to resonate with Gadamer’s meaningful rituals
and authority necessary for healing. Nonetheless, for Benedetti as he indicated in his
writings, placebo remained an interesting phenomenon that was useful to study and to
implement as a booster in active medical interventions by enhancing the contextual and
meaning-laden aspects of patient healing. He strongly opposed the use of placebo as a
separate healing method in its own right.
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I further presented evidence for considering placebo phenomenon a human
science subject rather than a natural science subject. I made that conclusion based on the
observation that contextual elements appeared to constitute placebo response. Many of
these contextual elements were dependent on human culture, history, and attitudes. I
further stated that psychopharmacological industry had been treating this phenomenon as
a natural science phenomenon similarly to the rest of medical interventions.
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Discussion
Why Science Is So Culturally Relevant
Modern Western society is embedded in a culture of perpetual anxiety. This may
seem like a strong statement until we observe how much we worry about our survival and
well-being at all times. This preoccupation with avoidance of harm is evident when one
notices the kind of laws humans in this society pass, the type of messages they give to
each other and to their children, and even the way they advertise products. The emphasis
on safety and health is strong.
It would logically follow that a society as anxious as ours needs a lot of
reassurances, a lot of certainty, and a lot of authority that Gadamer discussed in The
Enigma of Health (2004) to help soothe its anxiety. Understandably, science takes on the
role of such an authority that can provide an illusion of certainty, logic, predictability,
and ability to answer questions that humans are facing. When we observe this cultural
process from a hermeneutic point of view a so-called hermeneutic circle predictably
appears: the anxious society constructs a method for soothing its anxiety (i.e., science).
However, science, being the product of the anxious society, asks and answers questions
that perpetuate the anxiety rather than only soothe it. Thus a treatment created to deal
with one disorder, inevitably is criticized for risks it poses for creating another disorder or
a side effect. Now the society is worried not only about the disorder, but also about the
risks its treatment poses. Thus, science often does not eliminate fears, but multiplies
them instead.
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Despite the circular nature of science in modern Western culture, it provides
answers and a feeling of certainty, which are reassuring and calming (at least
temporarily) to the people in this culture.
Placebo Defined Contextually
Researchers in the Western scientific community have extensively studied
placebo response, which is often called placebo effect in the literature. They widely used
the phenomenon to prove efficacy of medications and to better understand various
neuropsychological mechanisms (Benedetti, 2009). Additionally, many researchers
attempted to understand the placebo response itself. One of the predominant hypotheses
used to understand placebo response included an idea that there existed a certain number
of placebo responders, people who were more likely to respond to placebo. With time,
that hypothesis became weaker as evidence suggested that placebo responders were not a
consistent group of individuals. In fact, the same individual might respond to placebo in
one study and not respond in another (Hoffman, Harrington, & Fields, 2005, p. 255) and
placebo responders and nonresponders could be created in a lab setting (Benedetti, 2013).
In recent years, understanding of placebo has taken a new turn where placebo response is
viewed as a contextual state-based phenomenon (Kong et al., 2013) rather than a traitbased phenomenon as previously hypothesized.
The new understanding of placebo response emphasizes the importance of context
and minimizes the contribution of personal traits. The new hypothesis appears more
beneficial in explaining certain inconsistencies. For instance, the state-based hypothesis
can explain the difficulties that the researchers encounter when using placebo in doubleblind studies or in studies of the placebo response itself. The state-based hypothesis does
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this in a way that the trait-based hypothesis could not. Hoffman et al. (2005) stated, “the
fact that we see such variation in the percentages of responders across different studies
further underscores the need for more research designed to tease out the contextual and
other factors that affect the likelihood of a response” (p. 255). Based on the wording
Hoffman and colleagues used, it was evident that they continued to view placebo
response as a phenomenon which was interwoven with the contextual variables rather
than itself created by those variables.
Medical and psychopharmacological research are applied sciences that are
governed by natural science ideals and logic. Therefore, these ideals and logic
predominate in the hypotheses and the assumptions made by researchers in medicine and
psychopharmacology. This logic was apparent throughout the Benedetti’s writings
(Benedetti, 2009, 2013) even when he endorsed the idea that context and relationship
with the treatment personnel were important contributors to a patient’s recovery. Even
though he admitted that context and relationships were important, Benedetti still viewed
those factors as contributing to placebo response and not as factors that were responsible
for creating the placebo response.
The theme that dominates the scientific literature on placebo response is that
layers of context can be peeled away to reveal the kernel that is placebo response.
Presumably, what is to be revealed is a psychobiological phenomenon representing the
innate ability of human mind to heal the mind and body. However, there is no evidence
that such a kernel actually exists. The idea appears to be based on a natural sciences
presumption that everything can always be broken into its constituting parts and then
further into smaller and smaller parts that constitute the constituting parts. However,

78
based on a hermeneutic understanding of context, under the layers there are only more
layers and no kernel. From hermeneutical point of view, the layers themselves are
valuable. The layers of context or the layers of meaning are what make up human
understanding of the world and the humans in it. Thus, I consider the contextual nature
of placebo response to be like an onion. One can peel away the onion’s layers one after
another and reveal nothing in the end. There will be no onion left. From a scientistic
point of view, on the other hand, one could see placebo response as an artichoke where
underneath all of the layers there can be found a heart.
The presumption that the smaller constituting parts exist follows the usual natural
sciences logic. In natural sciences, this presumption, indeed, is very helpful. It is a
presumption that allows scientists to identify key phenomena (i.e., independent variables)
and how they are affected by numerous identifiable confounding variables. This
presumption helps to understand physical phenomena and to explain how the physical
world around us functions. For example, humans have benefited greatly from science:
they build better shelters, produce more food, are able to tell what food is safe to eat and
what water is safe to drink. Nevertheless, I argue, based on Gadamer’s (2004) view of
human sciences, medicine, illness, and treatment that placebo response belongs in the
category of human sciences along with medicine.
Even though human sciences are forced to follow the logic of natural sciences, it
is rarely possible to do so. Human phenomena, particularly those that are to do with
psychology and relationships, have poor predictability. In accordance with natural
sciences model, psychology and even medicine both operate on probabilities and
statistical chances. Treatments of various psychological and medical conditions typically
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have percentage rates associated with them, with best treatment practices having most
data supporting their efficacy. The idea of empirically-based practice is based on the
natural science principles. However, this logic is not always best for treatment of specific
individuals. If most people are helped by a specific treatment, there is no guarantee that a
specific individual at the doctor’s office will be helped by this treatment. In home
improvement, however, the natural science logic works perfectly—if a special waterproof
coating covers a roof, it will deflect water no matter to what roof or who applies the
coating.
Conclusions of This Study
Science and scientific method are attractive as means of gaining knowledge in the
modern world. One of the reasons for popularity of science is its supposed neutrality and
impartiality. Other forms of knowledge gaining and research methods (e.g., case studies
and qualitative research methods) often have to prove that they too are valid options for
research as they are scrupulously compared to the natural science model. These other
methods are often accused of not being neutral enough. However, the assumption that
natural science model is neutral or impartial is false. Even though it aspires to be
impartial, scientific research is done by people and is designed to answer questions posed
by people. Since people are always embedded in their culture, they carry within them
their systems of values and meaning-making. Scientists cannot be completely impartial:
the topics they study and questions they pose for their research are all dictated by the
values scientists hold as individuals as well as cultural values that they perpetuate by
being embedded in the culture.
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The drug-taking and scientific research-oriented culture has been created by people
in the West and has perpetuated itself over the past decades. Placebos in the pill form are
sometimes found to be just as effective as medications (Howick et al., 2013).
One of the major legal changes that had an effect on the U.S. culture is the law
allowing for direct-to-consumer advertisement of prescription medications. The
therapeutic effect has been rising in both the placebo groups as well as in the active
medication groups during clinical trials (Biegler, 2014; Walsh et al., 2002) since the
implementation of the law. Study by Kamenica, Naclerio, and Malani (2013) showed
that exposure to brand-name advertisement can increase the efficacy of a medication
measured on the physiological level. Additionally, researchers acknowledged that the
consumers were led to believe that the medications were well-researched and were
superior to previously trusted treatments Biegler. Additionally, He (2015) stated that
such advertisement methods were misleading to the public and thus were harmful. I
argue that the reason why people believe the direct-to-consumer advertisement and have
an increased expectation of the power of medications is due to the scientific methods
being part of the Western culture. Thus, any association with research, research methods,
study, or tests taps into the general cultural understanding that these methods are what
bring healing.
In the context of double-blind psychopharmacological studies, most of the time
placebos are taken in the form of a pill. Therefore, the same cultural values, meanings,
and expectations apply to the placebos as they do to medications described above.
Additionally, culture-wide belief in scientific method and expectations of superiority of
science must affect research participants during psychopharmacological trials. During a
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study, research participants are constantly surrounded by the meaning-laden context of
“research,” “researchers,” “science,” “scientists,” “study,” “study doctor,” “medication”
and various other meaningful terms associated with science and research.
Context is larger than what clinical researchers assume. Benedetti (2013) and
clinical researchers concluded that context consisted of the following typical variables:
“words by doctors and personnel,” “color, shape, smell and taste of medications,” “sight
of health professionals, hospitals and medical instruments,” “interaction with other
patients and people,” “touched by needles and other devices,” “personal beliefs and
expectations,” and “memories about previous therapies” (p. 1209). However, I argue that
context is greater than what researchers can account for using positivistic approach.
Historically, people of the West have been living in a culture (i.e., context) that
predisposed them for believing in authority of science, superiority of quantitative
research, and trustworthiness of medications developed by scientists. This is in addition
to any individual cultural-historical systems of belief that each person carries with them.
Positivistic research cannot isolate or account for each one of these pieces that constitute
the greater context. Additionally, there is no way to predict how each one of the above
variables would affect a specific individual, because it is not known what meaning an
individual assigns to each of them.
Gadamer (2004) as well as other modern researchers (Bhugra & Ventriglio, 2015)
suggested that culture played a large role in healing and specifically in placebo response.
I believe culture therefore constitutes part of the context. Culture is a set of beliefs and
practices in any given place and time. Many of such beliefs are not conscious. They are
also dynamic and continue to change with time and be influenced by outside and inside
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forces. For instance, the mainstream Western culture’s belief in scientific approach to
exploring the world is both a conscious and an unconscious occurrence. People are
driven to scientific methods because they consider them superior to other methods of
knowledge gathering. In fact, the belief in scientific approach is so strong that simply an
association with the scientific process produces a halo effect. This blind belief in the
superiority of scientific method has been often used by marketing specialists. The belief
in superiority of scientific approach can be easily illustrated by an advertising example.
The marketing specialists appeal to the belief in superiority of scientific method by
stating in their advertisement videos and marketing spiels that the products have
undergone studies, research, and/or tests. They state this even in instances where there is
no evidence that such studies were conducted in accordance with best research practices.
They appeal to the society’s belief in science, because appealing to it works for selling
products. They do not have to produce credible research to be able to appeal to the
belief. In most instances where government regulations do not require a specific standard
for research, marketing specialists are free to mention any testing of a product to the
potential customers. There is no need to explain who exactly the researchers were, what
their credentials and expertise are, and how specifically they conducted their tests. Just
mentioning the fact that the product was tested by researchers produces the halo effect.
Strictly positivistic approach is not appropriate for practicing medicine. As
outlined in the previous section, placebo response belongs in the general category of
healing along with medicine. If the goal of medicine is to produce the best clinical
outcomes and make people feel better, then the medical field should not be benefiting
from the positivistic approach alone. Medicine is an applied science, which gathers
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important knowledge from various fields of natural science like biology, chemistry,
physics, etc. However, medicine could also benefit more from humanities and from less
emphasis on the positivistic approach. Because medicine deals with diseases that are
embedded in humans and in human nature, it is under the influence of the ever-changing
cultural dynamics. It is important to apply scientific research methods to treatment, but it
is inappropriate to consider the humanness of the healing experience inferior or less
important than the scientifically supported treatments. Within their positivistic
framework, Bhugra and Ventriglio (2015) and Benedetti (2013) agreed that paying
attention to the patient’s culture and to the doctor-patient relationship were both
important for promoting best healing practices. I argue that studying culture and
relationships should not be treated as another positivistic venture in isolating patterns and
probabilities. Perhaps, a qualitative research approach to these aspects would be more
beneficial than another quantitative inquiry that is likely to produce less meaningful
numbers. Similarly, a qualitative approach to healing by medicine might also prove
beneficial—connecting with the individual story of each patient might allow doctors to
find treatment methods that are more likely to help a specific individual.
Context influences humans on a biological level. It is difficult to overestimate
the importance of culture and context. Humans are greatly influenced by context.
Moreover, as hermeneutic approach suggests, they create the context and are, in fact,
embedded in the context that they create, thus creating a hermeneutic circle. The context
consists of the humans’ own thought processes, ideas, beliefs, and conscious and
unconscious influences of ever-changing culture. A human’s physiology is constantly
undergoing changes throughout lifetime: blood sugars fluctuate, blood pressure and heart
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beat change depending on activity and time of day, hormonal levels vary due to food
intake, emotional responses, and even due to body postures minute to minute (Carney et
al., 2010). Both thoughts and behaviors influence human physiology, increasing and
decreasing the neurochemicals in their brains and hormones in their bodies.
Conversations and relationships with other people influence physiology as well
(Cozolino, 2010). If Western doctors measure healing and illness by the biochemistry of
the body, because that is what can be measured with their instruments, it is irrational to
conclude that only biologically-based and scientifically-tested treatments are capable of
producing healing. There is abundant evidence to show that other contextual elements
are capable of producing biochemical changes (Carney et al., 2010; Cozolino, 2010).
Another strong example of the context influencing patients’ healing experience is
the recent study by Read, Cartwright, Gibson, Shiels, and Magliano (2015). They
conducted a survey of 1827 adults from New Zealand, which revealed interesting
findings about people’s beliefs surrounding their depression and the self-reported
effectiveness of their antidepressant medications. Specifically, Read and his colleagues
found a positive association between reported effectiveness of the medications and the
responders’ belief in the biogenetic etiology of depression. Similarly, there was a
positive correlation between the quality of the relationship with the prescribing doctor
and the respondents’ belief in the chemical imbalance as a cause of the depression.
Curiously, the researchers in this study also found a negative correlation between the
quality of the relationship with the prescribing doctor and the belief that unemployment
was the cause of the respondents’ depression. These findings appear to suggest that a
positive association with a person of science (i.e., the prescribing doctor) makes one more
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susceptible to view one’s illness through a lens of scientific explanations rather than
circumstantial or contextual ones. Additionally, findings of Read et al. suggested that
personal beliefs affected how one perceived his or her improvement and supported the
idea that personal understanding of cause and effect of illness might determine how well
someone responded to the active treatment. Though this study’s findings may not be
fully generalizable to the rest of the world’s population, the study had a rather large
sample of people who were indoctrinated into the Western medicine approach and thus
could reveal a trend that might be expected in the patients in other Westernized countries
such as the United States of America.
Cultures determine cognitive schema and interpretation of symbols of relevance
and importance within that culture. This is the crux of understanding placebo
response. However, this aspect of placebo response must be seen in the context of
how patients perceive their illness experience—what names and explanatory
models they give to it, but also the actual therapeutic communication and
encounter. (Bhugra & Ventriglio, 2015, p. 1)
Placebo response is a contextual phenomenon. Based on Gadamer’s (2004)
understanding of healing and illness, it appears that placebo response is a phenomenon of
restoration of the equilibrium that is created by context. Gadamer stated that healing
from an illness occurred through engaging in meaningful rituals that people associated
with healing. To Gadamer, health was an absence of illness and thus a state of the
equilibrium of all systems (i.e., mind, body, and environment being in balance). Illness,
on the other hand, was a loss of such an equilibrium. Therefore, healing needed to focus
on the restoration of the lost equilibrium and bring all systems back in balance. Taking a
pill in Western culture is a meaningful healing ritual. Therefore, placebo response that
follows taking a placebo pill is a healing response, because it is a meaningful healing
ritual which brings about the restoration of the equilibrium. Moerman and Jonas (2002)
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also observed that placebo response was a meaning response. Bhugra and Ventriglio
(2015) noted that “placebo response must be seen in the context of how patients perceive
their illness experiences—what names and explanatory models they give to it, but also
the actual therapeutic communications and encounter” (p. 1). Many if not most illnesses
are affected by contextual circumstances, because humans live in a meaning-laden world.
Notably, Miller, Colloca, and Kaptchuk (2009) argued that placebos affected the illness
rather than the disease:
Disease consists of biological dysfunction of the human organism—the primary
focus of diagnosis and treatment within biomedicine. Illness is the experience of
detriments to health, including the symptomatic manifestation of disease. Disease
adversely affects the organism; illness adversely affects the person. The body is
the locus of both disease and illness; however, the impact on the body is
understood differently in these two domains. Disease is understood scientifically
in terms of pathophysiology; illness is understood phenomenologically, as lived
experience. (p. 5)
This is supportive of the idea that placebo response is an equilibrium-restoring experience
using Gadamer’s terminology.
Bhugra and Ventriglio (2015) talked about expectations and speculated that what
the doctor provided to patients was meaning: “the key is what meaning patients give to
their experiences and distress which are culturally influenced” (p. 2).
I argue that placebo response is not simply influenced by various contextual
variables, as the medical field might see it. Instead, it appears that placebo response is
likely created by the individual as well as his or her historical context. Moreover, these
contextual variables that participate in creating placebo response are likely too numerous
and too dynamic to be able to account for using positivistic approach. Perhaps chaos
theory, as it was proposed for social sciences by Kiel and Elliott (1997), is a way to deal
with nonlinearity and uncertainty of human phenomena. The chaos theory and its
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potential application are too complex to be addressed at length by this theoretical
exploration and fall outside the scope of this study. Therefore, exploration of the
complex systems theory is not done in this contextual exploration of placebo response
definition and application to double-blind psychopharmacological studies. The
relationship of placebo phenomenon and chaos theory (also known as complex systems
theory) needs to be addressed by future research.
Implications for Double-Blind Psychopharmacological Studies
Some researchers suggested that clinical research studies could produce better
data by introducing treatment context similar to the one that existed in clinical practice
(Severus et al., 2012). Specifically, Severus and colleagues suggested that by setting an
expectation for the study participants that they were guaranteed to eventually receive
active treatment (i.e., receive regular-type medical care), researchers could improve the
placebo outcomes of the studies. In my working within the psychopharmacological
research industry, I learned from experience as a certified clinical research coordinator
that many clinical trial sites already provided free follow up treatment to the study
participants once the study was completed. Thus, it is reasonable to assume that the
participants have had the experience of a regular medical care and an expectation to be
eventually treated with an active medication as part of their participation.
The practice as described above is certainly more ethically appropriate than the
one that allows only chance to determine whether a participant receives an active
treatment. However, in my experience, following this practice did not improve the
outcome of the studies (i.e., it did not decrease the placebo response at a specific research
site). Moreover, the performance at clinical research sites that followed such practice
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was comparable to the performance of clinical research sites that did not provide follow
up treatment.
The psychopharmacological research industry continues to struggle with this
question: What are the variables that constitute the context of placebo response? I argue
that the better question to ask is: What are the context variables that constitute placebo
response? The answer, based on this study, is that the context variables appear to
constitute placebo response and are too numerous and too dynamic to be accounted for
using positivistic approach.
As the findings of this study suggest, medical practice is a healing practice
grounded in various cultural and historical influences. For the healing practice to be
useful, it has to be meaningful in the culture in which it has originated. Conventional
medicine originated in Western culture, which valued scientific methods and followed
positivistic ideas. Therefore, healing methods that incorporate science and scientific
methods are meaningful to the members of this culture and thus provide the healing that
they seek.
Healing effect comes, according to Gadamer (2004), from the restoration of the
lost equilibrium. The restoration of the equilibrium, on the other hand, is accomplished
by using the rituals and objects that the culture meaningfully associates with healing. In
Western culture’s conventional medicine, it is the meaning-laden visits to doctors,
measurement of vital functions, receipt of a prescription followed by a medicine regimen
that are associated with the process of healing in addition to caring relationships one
develops with medical personnel, staff, and/or family members. It is reasonable to
conclude, as Gadamer already has done in his The Enigma of Health (2004), that healing
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that follows a medical intervention in Western culture happens to the large degree due to
the meaning response.
Given the understanding that healing in Western culture occurs largely due to the
meaning that people associate with the healing rituals, it is possible to conclude that the
current ways of testing the efficacy of the psychopharmacological medications is less
than optimal. Currently, the double-blind method that uses placebo control group as a
comparator to active treatment exists within the context of the same meaning-laden
beliefs and rituals (e.g., belief in scientific research methods, going to the doctor, taking
medicine, etc.). If Gadamer’s conclusions are correct, the difference between placebo
and active medicine is rather small (particularly when it comes to psychotropic
medications) given the strength of the cultural and historical contextual influence. This
conclusion is also supported by some traditional scientific research: the meaning people
associate with their healing is powerful enough to override the effects of chemicals in
their bodies. Specifically, in studies done by Benedetti and colleagues (2003) as well as
by Levine, Gordon, Smith, and Fields (1981), even the proven pain relief treatment such
as morphine was significantly less effective when patient was unaware that they were
being administered a painkiller. It appears that a significant part of pain relief is coming
from the meaning patient associates with a ritual of being treated (the researchers of these
studies called it “expectations”).
Therefore, it is my conclusion that double-blind placebo control studies, as they
are conducted today, may not be the proper way to studying the efficacy of active
psychotropic medications. Positivistic double-blind placebo-controlled studies have been
the gold standard in pharmacological research under the assumption that in both active
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medication and placebo groups the conditions are equal aside from the active ingredient
in the medication. Thus, by attempting to isolate the healing to only the active ingredient
of the medication under study, the comparison of the two groups appeared justified.
Unfortunately, the context of pharmacological treatment in modern Western society has
been changing in the recent decades. The society has become more drug-focused than
ever with the ever-present direct-to-consumer pharmaceutical advertising. The
psychopharmaceutical industry has been particularly susceptible to the changes—the
placebo response in the placebo groups has been on the rise and detrimental to the
studies’ outcomes (Benedetti, 2009; Bridge et al., 2009; Song et al., 2010). There needs
to be a change in the way psychopharmacological industry tests its products.
Conducting Psychopharmacological Research by Incorporating Context
Benedetti (2013) encouraged incorporating what was known about placebo
response into healing by improving the doctors’ bedside manner and enhancing the
healing environment with encouraging words, etc. He concluded that placebo was a
contextual phenomenon. Gadamer (2004) made an even more overreaching conclusion
that all healing was about meaning-making in the context of cultural and historical
circumstances. Bhugra and Ventriglio (2015) also concluded that culture played a great
role in healing and should be incorporated in healing and research.
Indeed, placebo response appears to be a contextual phenomenon. It consists of
layers of context, which are both cultural-historical and individual ideas, beliefs, and
expectations. Thus, placebo response cannot be isolated by removing the layers of
context one after another. It is not possible, because context is larger than is generally
thought—it stretches to cultural-historical circumstances that people are embedded in and
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often take for granted without analyzing. Some healing practices simply make sense to
us—representatives of this date and time. Contextual phenomenon of placebo response
cannot be decontextualized. Therefore, attempts at limiting placebo response or
minimizing it are doomed to fail. Up until now, psychopharmacological research have
attempted to minimize placebo response across both placebo and active medication
groups.
Based on the findings of this contextual exploration, I suggest that one of the
ways to circumvent the issue with ever-rising placebo response is to maximize it instead.
Maximizing placebo response was exactly what Benedetti (2013) proposed for treatment
purposes. He acknowledged the significance of placebo response as a response to the
bedside manner and additionally hoped that this knowledge could be used by the health
professionals to “boost” their “empathic, humane, and compassionate behavior”
(p. 1238). He also added that understanding the effects of doctor-patient relationship
would improve “medical practice and clinical profession” and lead to a “better
social/communication skills and health policy” (p. 1238). Benedetti’s suggestions listed
above were limited to the medical treatment. I believe that one could also enhance
healing context for clinical research purposes.
In many efficacy studies of various new products, developers attempt to test their
inventions in conditions closely resembling real life utilization. For example, during
crash tests, new cars are smashed into concrete walls head on, sideways, and hit from
behind with another moving vehicle. These simulated high impact crashes at high speeds
and at different angles are important. They show the developers how the new car is
going to behave in similar difficult situations on the road. Will it prevent injuries to
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people inside? If the car does not perform up to the standards the developers set for
themselves, they go back to the drawing board and attempt to reinforce the identified
weak areas. Testing the car at slower speeds and in softer impact situations will not do
much for predicting its behavior in a real road accident.
Unfortunately, current ways of testing new psychiatric medications do not
resemble real life utilization. In real life, patients often come to a clinic, where they are
met with friendly personnel and calming music. They have pleasant conversations with
the staff and have a chance to discuss their illness with them. Then, they meet with a
physician or a psychiatrist with whom patients already have built (or have a chance to
build) a therapeutic relationship and whom they trust. After that, this clinician prescribes
them medications. The therapeutic context there is strong. Benedetti (2013) argued that
the doctor-patient relationship in a clinical setting should be further enhanced by
improving doctors’ bedside manner and should ensure that the healing potential was
maximized. Relationship with their doctors and reassurance by them have been shown to
affect people’s response to treatment. These are the therapeutic rituals, without which
drugs are less effective, according to Benedetti (Benedetti, 2013, p. 1234). In research
setting, however, medications and placebos are administered in double-blind fashion
under strict laboratory conditions. Any reassurance by the doctors and staff as well as
other typical medical office pleasantries are discouraged and minimized in an attempt to
reduce placebo response. The environment of a research clinic is supposed to feel cold to
patients by design. This cold laboratory environment does not match real life clinic
surroundings.
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Instead, I propose to incorporate the important meaning response and context into
research to bring the research conditions to closely resemble real life treatment.
Currently, psychopharmacological research is limited to laboratory and so-called clean
research environments. However, the purpose of the psychotropic drugs that are being
developed is to treat psychiatric conditions. Laboratory-based and research clinic-based
study treatments are too dissimilar from the typical treatment/healing environments of
psychiatrists’ offices. It would be more appropriate to conduct research of human
conditions (i.e., psychiatric illnesses and healing from such) in the environments that are
designed to be healing. The design of such studies can remain double-blind with active
medications and placebo-control groups. The major change I propose is maximizing the
placebo response across these groups instead of minimizing it. It can be done by
providing the most healing environment possible. Such environment Benedetti (2013)
recommended to create in general medical practice: increasing expectation of positive
effect and utilizing socially appropriate therapeutic rituals. Additionally, per
recommendation of Bhugra and Ventriglio (2015) cultural expectations for healing also
needed to be taken into account. This can be achieved by developing a therapeutic
rapport with each individual research participant through building a meaningful
relationship with him or her.
Once the contextual placebo response is maximized in both groups (active
medication and placebo), we can observe whether study medications are performing
better than placebos and have effects that are superior to the general healing environment.
Medications rigorously tested by such process, which pass the test of maximized healing
responses, are bound to be a great addition to the medical field as additional tools for
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healing people. These would be the effective medications that have proven themselves to
work in the real-life treatment conditions.
Summary of the Study
I conducted this theoretical exploration to address an important gap in the
literature—definition of placebo response. This was an attempt to bring together two
different schools of thought and break the artificial separation of humanities and
medicine. Introducing hermeneutics as a way to interpret medicine was not a novel idea.
Various scholars had explored this thought and agreed that medicine, despite its desire to
be seen purely as a natural science, was a study of meaning-making (Cooper, 1994;
Gadamer, 2004; Leder, 1990).
I concluded that using the philosophical lens of Hans-Georg Gadamer, placebo
response belonged in the area of human sciences (aka social sciences) and thus needed to
be understood as a human phenomenon. Additionally, placebo response is a context
phenomenon, not a human trait phenomenon, and the context appears to be greater than
researchers can generally account for using positivistic research methods. Context does
more than just influence someone’s experience—it influences humans on a biological
level too. Double-blind psychopharmacological studies cannot properly ascertain the
influence of medication versus placebo using the current design. Current double-blind
clinical studies attempt to equalize the contextual variables between placebo and
medication groups. However, the greater cultural context in modern Western world
dictates that scientific research, drugs, and allopathic medicine are healing and to be
trusted, thus increasing the efficacy of both placebo and medicine. This dynamic may
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change (strengthen or weaken) in the future with natural fluctuations and shifts in the
culture.
A different way of testing efficacy of psychotropic medications is necessary. By
maximizing the placebo response (i.e., meaningful healing context), researchers could put
medications to a much more realistic test. Medications that prove to be superior to
placebo under such conditions could indeed be considered a helpful addition to healing
process.
Culture is a dynamic entity. In the West, it is currently in a state of deep belief in
scientific progress and unlimited possibilities of science. However, science too has
limits. One of them is its inability to properly critique itself. It needs other theoretical
models to be able to address its own blind spots. Other philosophical approaches that
counterpoise the philosophical approach of natural science are necessary to effectively
look at its limitations. In summary, one should not forget that everything humans do and
create is produced within a context that has cultural and historical aspects.
Strengths and Limitations of the Study
This study is a theoretical exploration that used philosophical approach of HansGeorg Gadamer (hermeneutics) to critique and add to the current positivistic natural
science approach of modern clinical research. The strength of this study is offering a new
way of seeing the deficiencies of natural science model when it is applied to human (aka
social) sciences. There are a number of limitations to this study of placebo response.
First, the study aimed at outlining the deficiencies of psychopharmacology’s current
understanding of placebo response. I outlined one concrete suggestion to help the current
double-blind placebo-controlled design to better account for the complex contextual
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nature of placebo response. However, further research is needed for developing a more
comprehensive theory that specifically accounts for the dynamic context that creates
placebo response. Second, from the point of view of natural science, this study may
appear lacking in empirical support. However, this theoretical exploration did not aim to
provide concrete answers to the outlined issues with current state of placebo response
understanding. I hope that further research will be able to address these gaps. Third, as
with most philosophical theories, Gadamer’s hermeneutics is simply a way of looking at
and describing the cultural artifacts within a culture. Philosophical theories usually
provide a direction for future research, but rarely are able to serve as solutions
themselves. According to the findings of this study, it appears that placebo response is a
phenomenon that is created by context. Thus, the human experience within the context
needs to be explored further via means of qualitative research, instead of isolation or
streamlining of the potential context variables.
Phenomenon or phenomena? In this work, I consistently referred to placebo
response as a singular occurrence—placebo response phenomenon. However, some
researchers, including Benedetti (2009), talked about placebo effects and/or placebo
response phenomena—plural—in their writings. For the purposes of this contextual
exploration, it is irrelevant whether placebo response occurs via one or multiple
mechanisms in an organism. I concluded that whether placebo response or responses,
they occur as a result of a cultural historical and personal contexts. I did not explore in
this study specific physiological or other mechanisms via which organisms respond to
placebos.
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Suggestions for Further Research
In current placebo research, the terms placebo effect and placebo response are
commonly used interchangeably. Raz, Zigman, and de Jong (2009), who stated, “many
researchers and clinicians conflate placebo effects and placebo responses into one
transposable term” (para. 4), questioned this difference in terminology. Such
interchangeability initially appears insignificant. In the recent past, some of the
researchers acknowledged that the terms placebo response and placebo effect were used
interchangeably in the scientific community and literature (Benedetti, 2009; Colloca,
Sigaudo, & Benedetti, 2008) and some even attempted to change this inaccuracy by
suggesting that the two terms be distinguished from each other (Hoffman et al., 2005).
Hoffman et al. proposed that placebo effect would stand for the global outcome in the
placebo group and that placebo response would stand for the psychological phenomenon.
However, clinical trial investigators did not follow this suggestion (Benedetti, 2009, p. 6).
When measuring effect or response, clinical researchers are concerned with
describing measurable changes in an organism. Thus, when it comes to
interchangeability of the two terms, one might consider a different point of view. Both
words effect and response can similarly describe such changes. However, in the world of
linguistic nuances and intricate meanings, using the terms placebo response and placebo
effect hardly means the same thing. When one talks of the effects of something, it is
presumed that the subject is affecting the object in some important way where changes
are observable and/or measurable. When one describes the response of something, the
agency changes. Now the subject is what undergoes the changes in the presence of the
object whether the object actively affects the subject or not.
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Therefore, when one talks about placebos it would be improper to talk about
placebo effects, since placebos by definition are inert and are incapable of producing an
effect. However, placebo response is a more fitting description of the phenomenon. It
implies that some changes occur in the subject whereas the object, placebo, may not
necessarily be the one causing the changes to occur. Moreover, when one describes the
changes in organism due to medications, it is appropriate to talk about the medication
effects, because it is the medical community’s presumption that medications are active
and are capable of producing effects. Medication response is an unusual term, yet it
would also be appropriate for describing the reactions to or effects of the medication. In
double-blind psychopharmacological studies, however, the comparison is of medication
effects to placebo response and such comparison may not be fully justified.
Additionally, it would be important to investigate in the future the differences in
the use of the terms placebo effect and placebo response in the scientific literature. Raz
et al. (2009) identified important effects of the interchangeable use of the terms in the
literature:
Lack of uniformity underscores inherent ambiguity and fosters a climate of
uncertainty. Moreover, it may adversely influence the direction and nature of
research efforts. In addition, placebolike effects often occur without the
administration of an actual placebo, highlighting the central role of expectation
and suggestion in placebo-related phenomena. (para. 4)
Given the assumptions identified in Benedetti’s (2009, 2013) overviews of
placebo research, it is reasonable to assume that psychotherapy community and clinical
psychology field in general might be more likely to use the term placebo response,
whereas the medical community is less likely to differentiate between the two terms.
Future research is needed to find out whether such differences exist and if they do, what
they can tell about the attitude towards placebo and the self-healing properties of humans.
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The ever-changing nature of contextual variables that constitute culture is
impossible to predict and constructively use by the methods of natural science’s
positivistic approach. It appears that a different model is needed for understanding
context. Some of the potential approaches include qualitative methods of study where
individual human experiences of phenomena are studied and themes are identified
(Creswell, 2012). This approach has been successfully used in the past to understand the
placebo response phenomenon (Kaptchuk et al., 2009; Sandler et al., 2008; Thompson et
al., 2009). The results of such studies informed the researchers about the commonalities
in experience without reducing the human experience to numbers. Instead, meaningful
and relatable themes were identified. Placebo response research would benefit from an
increase in research that uses qualitative methodologies.
Alternatively, a mathematical model of chaos theory could potentially help
researchers understand placebo response as a dynamic system. This theory was proposed
to solve issues with social sciences by Kiel and Elliott (1997). More research in this area
is needed to ascertain whether chaos theory could be a helpful model for understanding
the dynamics of contextual phenomena such as placebo response.
Moreover, psychiatric medications appear to be sometimes helpful to people.
This is probably due to the combination of both the contextual as well as the biological
effects on the human body. Thus, the clinical studies of the psychiatric medications are
necessary to insure that the medications that are put on the market are safe. However, it
is difficult to judge the efficacy of psychiatric medications using the positivistic approach
and placebo as a comparator because context determines response in both placebo groups
and active medication groups. In this study, I proposed a change to the current double-
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blind clinical study design that could better incorporate context. The proposed design
would not exclude context as a nuisance variable when testing psychiatric medications.
Instead, the new design would embrace the context and placebo response factors. By
maximizing healing context, researchers might be able to develop medications that truly
contribute to the healing of individuals beyond meaning-response.
Lastly, the concepts placebo and placebo response or placebo effect themselves
carry meaning in Western culture. For instance, Huculak (2013) explored the views
associated with these concepts using a keywords approach. She noted that placebo had
pejorative views associated with it. However, placebo effect was “more nuanced”
(p. 164). Undoubtedly, these sudden differences are likely to have an effect on
someone’s perception of placebo and the response associated with it. In many ways, this
negative interpretation of placebo is already playing a role in the way researchers are
treating it and in the way they interpret study results. It would be important to explore
these differences further via both quantitative and qualitative approaches in patients and
in doctors.
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